Sinovac Biotech (SVA) 20-F29 Apr 152014 FY Annual report (foreign)Financial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	12 Months Ended
Document and Entity Information	Dec. 31, 2014
Document and Entity Information
Entity Registrant Name	SINOVAC BIOTECH LTD
Entity Central Index Key	1084201
Document Type	20-F
Document Period End Date	31-Dec-14
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding	55,809,661
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Current assets
Cash and cash equivalents	$91,518	$107,242
Accounts receivable - net (notes 3 and 9)	40,757	31,927
Inventories (note 4)	18,832	14,329
Prepaid expenses and deposits (including prepaid expenses to related party of 2014 - $157, 2013 - $161) (note 10 (b))	1,430	1,150
Deferred tax assets (note 12)	2,266	2,602
Total current assets	154,803	157,250
Property, plant and equipment (notes 6 and 9)	68,417	67,963
Prepaid land lease payments (note 7)	10,405	10,948
Long-term inventories (note 5)	2,648	2,781
Prepaid expenses (including prepaid expenses to related party of 2014 - $232, 2013 - $145) (note 10 (b))	3	154
Prepayments for acquisition of equipment	1,387	708
Deferred tax assets (note 12)	515	117
Licenses (note 8)	352	772
Total assets	238,530	240,693
Current liabilities
Short-term bank loans and current portion of long-term debt (note 9)	47,375	16,217
Loan from a non-controlling shareholder (note 10(a))	2,595	3,324
Accounts payable and accrued liabilities (note11)	23,237	28,037
Income tax payable (note 12)	1,101	246
Deferred revenue (note 13)	4,996	875
Deferred government grants (note 14)	530	458
Total current liabilities	79,834	49,157
Deferred government grants (note 14)	7,494	4,746
Long-term debt (note 9)	1,803	32,146
Deferred revenue (note 13)	7,191	11,005
Other non-current liabilities (note 12)	482
Total long-term liabilities	16,970	47,897
Total liabilities	96,804	97,054
Commitments and contingencies (notes 15 and 22)
EQUITY
Preferred stock Authorized 50,000,000 shares at par value of $0.001 each Issued and outstanding: nil
Common stock (note 16) Authorized: 100,000,000 shares at par value of $0.001 each Issued and outstanding: 55,809,661 (2013-55,570,361)	56	56
Additional paid-in capital	108,243	107,393
Accumulated other comprehensive income	12,022	14,141
Statutory surplus reserves (note 18)	12,627	11,808
Accumulated deficit	-6,384	-4,714
Total shareholders' equity	126,564	128,684
Non-controlling interests (note 19)	15,162	14,955
Total equity	141,726	143,639
Total liabilities and equity	$238,530	$240,693

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Consolidated Balance Sheets
Prepaid expense to related party, current (in dollars)	$157	$161
Long-term prepaid expense to related party (in dollars)	$232	$145
Preferred stock, Authorized shares	50,000,000	50,000,000
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, Issued shares	0	0
Preferred stock, outstanding shares	0	0
Common stock, Authorized shares	100,000,000	100,000,000
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, Issued shares	55,809,661	55,570,361
Common stock, outstanding shares	55,809,661	55,570,361

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (Loss) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Consolidated Statements of Comprehensive Income (Loss)
Sales (note 21)	$63,101	$72,524	$49,216
Cost of sales	16,493	21,273	19,100
Gross profit	46,608	51,251	30,116
Selling, general and administrative expenses (including rent expenses incurred to related party of 2014 - $869, 2013 - $847, 2012 - $823) (note 10(b))	34,787	34,538	33,280
Provision (recovery) for doubtful accounts	329	-504	-874
Research and development expenses - (net of 2014- $nil, 2013- $nil, 2012- $125 in government research grants)	11,034	8,384	17,044
Loss on disposal and impairment of property, plant and equipment (note 6)	74	88	2,190
Government grants recognized in income	-104		-373
Total operating expenses	46,120	42,506	51,267
Operating income (loss)	488	8,745	-21,151
Interest and financing expenses - (net of 2014-$81, 2013-$65, 2012 - $1,458, in interest subsidies, Including interest expenses incurred to related party, 2014 - $221, 2013 - $237, 2012 - $231)	-3,407	-3,031	-775
Interest income	2,685	2,168	2,370
Other income (expenses)	1,356	263	-77
Income (loss) before income taxes and non-controlling interests	1,122	8,145	-19,633
Income tax benefit (expense) (note 12)	-1,458	2,225	884
Net income(loss)	-336	10,370	-18,749
Less: (income) loss attributable to non-controlling interests	-515	-2,928	3,896
Net income (loss) attributable to shareholders of Sinovac	-851	7,442	-14,853
Other comprehensive income(loss), net of tax of nil
Foreign currency translation adjustments	-2,427	2,686	2,024
Total comprehensive income (loss)	-2,763	13,056	-16,725
Less: comprehensive (income) loss attributable to non-controlling interests	-207	-3,244	3,665
Comprehensive income (loss) attributable to shareholders of Sinovac	($2,970)	$9,812	($13,060)
Basic and diluted earnings(loss) per share (note 20) (in dollars per share)	($0.02)	$0.13	($0.27)
Weighted average number of shares of common stock outstanding
- Basic (in shares)	55,681,076	55,301,276	54,926,440
- Diluted (in shares)	55,681,076	55,802,338	54,926,440

Consolidated_Statements_of_Com1

Consolidated Statements of Comprehensive Income (Loss) (Parenthetical) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Consolidated Statements of Comprehensive Income (Loss)
Rent expenses incurred to related party	$869	$847	$823
Research and development expenses, government research grants	0	0	125
Interest and financing expenses, subsidies	81	65	1,458
Interest and financing expenses incurred to related party	221	237	231
Tax effect of other comprehensive income (loss)	$0	$0	$0

Consolidated_Statements_of_Sha

Consolidated Statements of Shareholders' Equity (USD $)	Total shareholders' equity	Common stock	Additional paid-in capital	Accumulated other comprehensive income (foreign currency translation adjustment)	Statutory surplus reserves	Retained earnings (accumulated deficits)	Non-controlling interests	Total
In Thousands, except Share data, unless otherwise specified	Total shareholders' equity	Common stock	Additional paid-in capital		Statutory surplus reserves	Retained earnings (accumulated deficits)	Non-controlling interests	Total
Balance at Dec. 31, 2011	$129,921	$55	$105,383	$9,978	$11,808	$2,697	$15,376	$145,297
Balance (in shares) at Dec. 31, 2011		54,773,961
Increase (Decrease) in Equity
Stock-based compensation	347		347					347
Exercise of stock options (note 16)	508		508					508
Exercise of stock options (in shares) (note 16)		317,600						317,600
Subscriptions received (note 16)	8		8					8
Other comprehensive income
- Other comprehensive income attributable to non-controlling interests							231	231
- Other comprehensive income attributable to shareholders	1,793			1,793				1,793
Net income (loss) for the year
- Net income (loss) attributable to non-controlling interests							-3,896	-3,896
- Net income (loss) attributable to shareholders of Sinovac	-14,853					-14,853		-14,853
Balance at Dec. 31, 2012	117,724	55	106,246	11,771	11,808	-12,156	11,711	129,435
Balance (in shares) at Dec. 31, 2012		55,091,561
Increase (Decrease) in Equity
Stock-based compensation	281		281					281
Exercise of stock options (note 16)	849	1	848					849
Exercise of stock options (in shares) (note 16)		478,800
Subscriptions received (note 16)	18		18					18
Other comprehensive income
- Other comprehensive income attributable to non-controlling interests							316	316
- Other comprehensive income attributable to shareholders	2,370			2,370				2,370
Net income (loss) for the year
- Net income (loss) attributable to non-controlling interests							2,928	2,928
- Net income (loss) attributable to shareholders of Sinovac	7,442					7,442		7,442
Balance at Dec. 31, 2013	128,684	56	107,393	14,141	11,808	-4,714	14,955	143,639
Balance (in shares) at Dec. 31, 2013		55,570,361						55,570,361
Increase (Decrease) in Equity
Stock-based compensation	287		287					287
Exercise of stock options (note 16)	512		512					512
Exercise of stock options (in shares) (note 16)		239,300
Subscriptions received (note 16)	51		51					51
Other comprehensive income
- Other comprehensive income attributable to non-controlling interests							-308	-308
- Other comprehensive income attributable to shareholders	-2,119			-2,119				-2,119
Net income (loss) for the year
- Net income (loss) attributable to non-controlling interests							515	515
- Net income (loss) attributable to shareholders of Sinovac	-851					-851		-851
Transfer to statutory surplus reserves					819	-819
Balance at Dec. 31, 2014	$126,564	$56	$108,243	$12,022	$12,627	($6,384)	$15,162	$141,726
Balance (in shares) at Dec. 31, 2014		55,809,661						55,809,661

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash flows provided by (used in) operating activities
Net income (loss)	($336)	$10,370	($18,749)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
- Deferred income taxes	-162	-2,225	-17
- Stock-based compensation	287	281	347
- Inventory provision	1,273	1,399	3,479
- Provision (recovery) for doubtful accounts	329	-504	-874
- Loss on disposal and impairment of property, plant and equipment	74	88	2,190
- Research and development expenditures qualified for government grant	0	0	-125
- Depreciation of property, plant and equipment and amortization of licenses	8,142	6,433	4,189
Amortization of the prepaid land lease payments	278	311	299
- Deferred government grant recognized in income	-104		-358
- Accretion expenses	114	100	235
Changes in:
- Accounts receivable	-9,691	-7,256	-4,286
- Inventories	-6,170	-7,547	-426
- Income tax payable	899	7	-3,130
- Prepaid expenses and deposits	-496	242	913
- Deferred revenue	601	-675	1,026
- Accounts payable and accrued liabilities	-4,167	4,552	-967
- Other non-current liabilities	482
Net cash provided by (used in) operating activities	-8,647	5,576	-16,254
Cash flows provided by financing activities
- Proceeds of bank loans	17,837	16,800	16,787
- Repayments of bank loans	-15,962	-4,089	-4,755
- Proceeds from issuance of common stock, net of share issuance costs	512	848	508
- Proceeds from shares subscribed	51	18	8
- Dividends paid to a non-controlling shareholder			-802
- Government grants received	3,520	842	2,395
- Repayment of loan from a non-controlling shareholder	-649
- Proceeds of loan from a non-controlling shareholder			3,189
Net cash provided by financing activities	5,309	14,419	17,330
Cash flows used in investing activities
- Proceeds from disposal of equipment			5
- Acquisition of property, plant and equipment	-11,003	-5,176	-16,156
Net cash used in investing activities	-11,003	-5,176	-16,151
Exchange gain (loss) on cash and cash equivalents	-1,383	1,182	2,029
Increase (decrease) in cash and cash equivalents	-15,724	16,001	-13,046
Cash and cash equivalents, beginning of year	107,242	91,241	104,287
Cash and cash equivalents, end of year	91,518	107,242	91,241
Supplemental disclosure of cash flow information:
Cash paid for interest	3,152	2,853	750
Cash paid for income taxes	491		2,265
Supplemental schedule of non-cash activities:
Acquisition of property, plant and equipment included in accounts payable and accrued liabilities	$2,209	$2,270	$3,788

Basis_of_Presentation

Basis of Presentation	12 Months Ended
Basis of Presentation	Dec. 31, 2014
Basis of Presentation
Basis of Presentation
	1.Basis of Presentation

	These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”). They include the accounts of Sinovac Biotech Ltd., which is incorporated under the laws of Antigua and Barbuda, and its wholly owned or controlled subsidiaries (collectively, the “Company”). All significant intercompany transactions have been eliminated. Details of the Company’s subsidiaries are as follows:

	Name	Date of	Place of	Percentage of	Percentage of	Principal activities
		incorporation or	incorporation	ownership as	ownership as of
		establishment	(or	of December	December 31, 2013
			establishment)	31, 2014
			/operation
	Sinovac Biotech (Hong Kong) Ltd (“Sinovac Hong Kong”)	Oct-08	Hong Kong	100%	100%	Investment holding company

	Sinovac Biotech Co., Ltd. (“Sinovac Beijing”) (note 19)	Apr-01	People’s Republic of China (“PRC”)	73.09%	73.09%	Research and development, production and sales of vaccine products

	Tangshan Yian Biological Engineering Co., Ltd. (“Tangshan Yian”)	Feb-93	PRC	100%	100%	Research and development, production and sales of vaccine products

	Sinovac Biological Technology Co., Ltd. (“Sinovac R&D”)	May-09	PRC	100%	100%	Research and development of vaccine products

	Sinovac (Dalian) Vaccine Technology Co., Ltd. (“Sinovac Dalian”) (note19)	Jan-10	PRC	55%	55%	Research and development, production and sales of vaccine products

Significant_Accounting_Policie

Significant Accounting Policies

12 Months Ended

Dec. 31, 2014

Significant Accounting Policies

2.Significant Accounting Policies

(a)Use of Estimates

In preparation of the Company’s consolidated financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting periods. Significant estimates made by management include: provision for product returns, allowance for doubtful accounts, inventory provisions, useful lives of amortizable intangible assets, impairment of long-lived assets, and realizability of deferred tax assets. On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company’s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company’s consolidated financial statements could be materially impacted.

(b)Cash and Cash Equivalents

Cash equivalents consist of highly liquid investments that are readily convertible to cash generally with maturities of three months or less when purchased.

(c)Accounts Receivable

The Company extends unsecured credit to its customers in the ordinary course of business and actively pursues past due accounts. The Company estimates an allowance for doubtful accounts based on historical experience, the age of the accounts receivable balances, credit quality of the Company’s customers, current economic conditions and other factors that may affect its customers’ ability to pay.

(d)Inventories

Inventories are stated at the lower of cost or replacement cost with respect to raw materials and the lower of cost or net realizable value with respect to finished goods and work in progress. The cost of work in progress and finished goods is determined on a weighted-average cost basis and includes direct material, direct labor and overhead costs. Net realizable value represents the anticipated selling price, net of distribution cost, less the cost for finished goods or estimated costs to completion for work in progress.

(e)Property, Plant and Equipment

Property, plant and equipment are recorded at cost. Significant additions and improvements are capitalized, while repairs and maintenance are charged to expenses as incurred. Equipment purchased for specific research and development projects with no alternative uses are expensed. Assets under construction are not depreciated until construction is completed and the assets are ready for their intended use. Gains and losses from the disposal of property, plant and equipment are recorded in loss on disposal and impairment of property, plant and equipment included in the consolidated statements of comprehensive income (loss).

Depreciation of property, plant and equipment is computed using the straight-line method based on the estimated useful lives of the assets as follows:

Plant and buildings

10 to 24 years

Machinery and equipment

8 to 10 years

Motor vehicles

4 to 5 years

Office equipment and furniture

3 to 5 years

Leasehold improvements

Lesser of useful lives and term of lease

(f)Prepaid land lease payments

Prepaid land lease payments represent amounts paid for the rights to use land in the PRC and is recorded at purchase cost less accumulated amortization. Amortization is provided on a straight-line basis over the term of the lease agreement, which is 28 to 49 years.

(g)Licenses

The Company capitalizes the patent payment and the purchase cost of vaccines if the vaccine has received a new drug certificate from the China Food and Drug Administration (“CFDA”) of China. If the vaccine has not received a new drug certificate, the purchase cost is expensed as in-process research and development.

Licenses in relation to the production and sales of pharmaceutical products are amortized on a straight-line basis over their respective useful lives. The useful lives of inactivated hepatitis A and recombinant hepatitis A&B licenses are estimated to be ten years. Before August 15, 2012, the useful life for H5N1 licenses was estimated to be 20 years. Effective August 15, 2012, the remaining useful life was revised to three years expiring on December 29, 2015 as a result of amendment to the agreement with the licensor (note 22(c)). The weighted average useful lives of the acquired licenses are 9.16 years. Costs incurred to renew or extend the term of a licenses are capitalized and amortized over the license’s useful life on a straight-line basis.

(h)Impairment of Long-Lived Assets

Long-lived assets including intangible assets subject to amortization are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of an asset group may not be recoverable from the future undiscounted net cash flows expected to be generated by the asset group. An asset group is identified as assets at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets. If the asset group is not fully recoverable, an impairment loss would be recognized for the difference between the carrying value of the asset group and its estimated fair value, based on the discounted net future cash flows or other appropriate methods, such as comparable market values. The Company uses estimates and judgments in its impairment tests and if different estimates or judgment had been utilized, the timing or the amount of any impairment charges could be materially different. The Company recorded impairment charges on long-lived assets for the year ended December 31, 2014 of $nil (2013 - $57, 2012 - $2,176).

(i)Income Taxes

The Company follows the liability method of accounting for income taxes. Under this method, deferred tax liabilities and assets are determined based on the temporary differences between the financial statements and tax bases of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance is provided if, based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates and laws.

The tax benefit from an uncertain tax position is recognized only if it is more likely than not that the tax position will be sustained upon examination by the appropriate taxing authority, based on the technical merits of the position. The tax benefits recognized from such a position are measured based on the amount that is greater than 50% likely of being realized upon settlement. The Company recognizes a change in available facts after the reporting date but before issuance of the financial statements in the period when the change in facts occur, even if that new information provides a better estimate of the ultimate outcome of an uncertainty. Liabilities associated with uncertain tax positions are classified as long−term unless expected to be paid within one year. Interest and penalties related to uncertain tax positions, if any, are recorded in the provision for income taxes and classified with the related liability on the consolidated balance sheets.

(j)Value-added Taxes

Value-added taxes (“VAT”) collected from customers relating to product sales and remitted to governmental authorities are presented on a net basis. VAT collected from customers is excluded from revenue. Prior to July 1, 2014, the Company was subject to a VAT rate of 6%. Starting on July 1, 2014, the Company is subject to a VAT rate of 3%.

(k)Revenue Recognition

Revenue is recognized when persuasive evidence of an arrangement exists, the price is fixed and determinable, delivery has occurred and there is a reasonable assurance of collection of the sales proceeds. The Company generally obtains purchase authorizations from its customers for a specified amount of products at a specified price and considers delivery to have occurred when the customer takes title of the products. The Company provides certain customers with a right of return.

Revenue for inactivated hepatitis A, combined inactivated hepatitis A&B and seasonal influenza vaccines are recognized when delivery has occurred and the Company estimates return provision for these products. The product return provisions for inactivated hepatitis A vaccine and combined inactivated hepatitis A&B vaccine are estimated based on historical return and exchange levels as well as the inventory levels and the remaining shelf lives of the products in the distribution channels. As of December 31, 2014, the sales return provision for inactivated hepatitis A vaccine and combined inactivated hepatitis A&B vaccine was $3,553 (December 31, 2013 - $2,240). Private pay sales return provision of inactivated hepatitis A and combined inactivated hepatitis A&B as a percentage of sales was 8.6% and 5.5% in 2014 and 2013, respectively. The Company does not accept returns for hepatitis products sold under the Expanded Program on Immunization and exports. As such, no sales returns are estimated for these sales. The product return provision for seasonal influenza vaccines is estimated based on actual sales returns and expected sales returns up to the end of the flu season because the Company generally accepts returns before the end of the flu season. As of December 31, 2014, the sales return provision for seasonal influenza vaccine returns was approximately $1,320 (December 31, 2013 - $575).

Revenue for animal and mumps vaccines without a right of return provided to customers is recognized when delivery has occurred. Revenue for animal and mumps vaccines with a right of return provided to customers is recognized when payments are collected from customers as the Company currently does not have sufficient historical data to estimate returns for these products.

Deferred revenue is generally relating to government stockpiling programs and advances received from customers. For government stockpiling programs of H1N1 and H5N1 vaccines, the Company generally obtains purchase authorizations from the government for a specified amount of products at a specified price and no rights of return are provided. Revenue is recognized when the government takes delivery of the products. If the products expire prior to delivery, these expired products are recognized as revenue once cash is received and the products have expired and passed government inspection.

(l)Shipping and Handling

Shipping and handling fees billed to customers are included in sales. Costs related to shipping and handlings are recognized in selling, general and administrative expenses in the consolidated statements of comprehensive income (loss). For the year ended December 31, 2014, $1,241 of shipping and handling costs was included in selling, general and administrative expenses (2013 - $1, 235, 2012 - $1,118).

(m)Advertising Expenses

Advertising costs are expensed as incurred and included in selling, general and administrative expenses. Advertising costs were $268 for the year ended December 31, 2014 (2013 - $474, 2012 - $29).

(n)Research and Development

Research and development (“R&D”) costs are expensed as incurred and are disclosed as a separate line item on the Company’s consolidated statements of comprehensive income (loss). R&D costs consist primarily of the remuneration of R&D staff, depreciation, material, clinical trial costs as well as amortization of acquired technology and know-how used in R&D with alternative future uses. R&D costs also include costs associated with collaborative R&D and in-licensing arrangements, including upfront fees paid to collaboration partners in connection with technologies which have not reached technological feasibility and did not have an alternative future use. Reimbursement of R&D costs for arrangements with collaboration partners is recognized when the obligations are incurred.

Under certain R&D arrangements with third parties, the Company may be required to make payments that are contingent on the achievement of specific development, regulatory and/or commercial milestones. Before a product receives regulatory approval, license fees and milestone payments made to third parties are expensed as incurred. License fees and milestone payments made to third parties after regulatory approval is received are capitalized and amortized over the remaining life of the agreement with third parties.

(o)Government Grants

Government grants received from the PRC government by the PRC operating subsidiaries of the Company are recognized when there is reasonable assurance that the amount is receivable and all the conditions specified in the grant have been met. Government grants for R&D are recognized as a reduction to R&D expenses when the expenses are incurred in the same period when the conditions attached to the grants are met, or recognized as government grants recognized in income in the period when the conditions are met after the expenses are incurred. Government grants for property, plant and equipment are deferred and recognized as a reduction to the related depreciation and amortization expenses in the same manner as the plant and equipment are amortized. Interest subsidies are recorded as a reduction to interest and financing expenses in the consolidated statements of comprehensive income (loss), or recorded as a reduction to interest capitalized if the subsidies granted are related to a specific borrowing associated with building a qualifying asset. For government loans received at below market interest rate, the difference between the face value of the loan and fair value using the effective interest rate method is recorded as deferred government grants. Accretion expense is recorded in interest and financing expense and the government grant will be recognized as “government grants recognized in income” in the consolidated statement of comprehensive income (loss) when the government loan is fully repaid.

(p)Retirement and Other Post-retirement Benefits

Full-time employees of the Company in the PRC participate in a government mandated defined contribution plan pursuant to which certain pension benefits, medical care, unemployment insurance, employee housing fund and other welfare benefits are provided to employees. Chinese labor regulations require that the Company makes contributions to the government for these benefits based on certain percentages of the employees’ salaries. The Company has no legal obligation for the benefits beyond the contributions. The total amounts for such employee benefits, which were expensed as incurred was $3,498 for the year ended December 31, 2014 (2013 - $3,138, 2012 - $2,771).

(q)Foreign Currency Translation and Transactions

The Company maintains their accounting records in their functional currencies, U.S. dollars (“US$”) for the Company and Sinovac Hong Kong and Renminbi Yuan (“RMB”) for the PRC subsidiaries. The Company uses the US$ as its reporting currency.

At the transaction date, each asset, liability, revenue and expense is re-measured into the functional currency by the use of the exchange rate in effect at that date. At the period end, foreign currency monetary assets, and liabilities are re-measured into the functional currency by using the exchange rate in effect at the balance sheet date. The resulting foreign exchange gains and losses are included in selling, general and administrative expenses. The Company recognized foreign exchange gains (losses) of $(647) for the year ended December 31, 2014 (2013 - $650, 2012 - $207).

The assets and liabilities of the PRC subsidiaries, Sinovac Beijing, Tangshan Yian, Sinovac R&D and Sinovac Dalian are translated into US$ at the exchange rates in effect at the balance sheet date. Revenue and expenses are translated at average exchange rates. Gains and losses from such translations are recorded in accumulated other comprehensive income, a component of shareholders’ equity.

Gains and losses on intra-entity foreign currency transactions that are of a long-term-investment nature was $294 for year ended December 31, 2014 (2013 - $235, 2012 - $199) which was recorded in other comprehensive income (loss).

(r)Stock-based Compensation

Compensation expense for costs related to all share-based payments, including grants of stock options, is recognized through a fair-value based method. The Company uses the Black-Scholes option-pricing model to determine the grant date fair value for the awards. The Company has elected to recognize share-based compensation costs using the straight-line method over the requisite service period with a graded vesting schedule, provided that the amount of compensation costs recognized at any date is at least equal to the portion of the grant date value of the awards that are vested at that date. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from initial estimates. Share based compensation costs are recorded net of estimated forfeitures such that expense is recorded only for those awards that are expected to vest.

(s)Comprehensive Income (loss)

The Company’s comprehensive income (loss) consists of net income (loss) and foreign currency translation adjustments.

(t)Earnings(loss) Per Share

Earnings (loss) per share is calculated in accordance with ASC 260 Earnings per Share. Basic earnings (loss) per share is computed by dividing the net income (loss) attributable to shareholders of Sinovac by the weighted average number of common shares outstanding during the year. Diluted earnings per share is computed in accordance with the treasury stock method and based on the weighted average number of common shares and dilutive common share equivalents of options. If the Company records a net loss, the basic and diluted loss per share is the same because the exercise of options would have an anti-dilutive effect.

(u)Operating Leases

Leases are classified as capital and operating depending on the terms and conditions of the lease agreement. Leases that transfer substantially all the benefits and risks incidental to ownership of assets are accounted for as if there was an acquisition of an asset and incurrence of an obligation at the inception of the lease. All other leases are accounted for as operating leases where rental payments are expensed as incurred. There are no capital leases for the periods presented.

(v)Fair Value Measurements

Assets and liabilities subject to fair value measurements are required to be disclosed within a specified fair value hierarchy. The fair value hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following categories based on the lowest level input used that is significant to a particular fair value measurement:

Level 1 — Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2 — Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets and liabilities in markets that are not active.

Level 3 — Unobservable inputs for the asset or liability.

As of December 31, 2014 and 2013, the Company did not have any financial assets or liabilities measured at fair value on a recurring basis.

The carrying values of cash equivalents, accounts receivable, accounts payable and accrued liabilities and short-term bank loans and the current portion of long-term debt approximate their fair value because of their short-term nature. The fair value of long-term debt is estimated based on the discounted value of future contractual cash flows which approximates their carrying value due to the fact they are predominately stated at variable rates based on the People’s Bank of China. Fair value of cash equivalents and the long-term debt are determined based on level 2 inputs.

The Company measures property, plant and equipment at fair value on a non-recurring basis only if an impairment charge were to be recognized. As at December 31, 2012, the Company’s prepaid land lease payment, property, plant and equipment at Tangshan Yian and certain equipment and leasehold improvements at Sinovac Beijing were measured at fair value on a nonrecurring basis. The Company determined the fair value of Tangshan Yian’s prepaid land lease payments, plant and buildings using the market approach by obtaining quoted prices for similar assets in the principal resale market. The Company determined the fair value of Tangshan Yian’s machinery and equipment using the cost approach by estimating the amount that currently would be required to construct or purchase substitute machinery and equipment of comparable utility. The estimate considers the condition of the assets which include the physical deterioration and economic obsolescence. It was determined the fair value of Tangshan Yian’s property, plant and equipment was $2,923 compared to the carrying value of $4,420. The Company determined the fair value of certain equipment and leasehold improvements at Sinovac Beijing using the market approach by obtaining quoted prices for similar assets in the principal resale market, and determined the fair value was $89 compared to the carrying value of $763. There were no non-recurring fair value measurements for the years ended December 31, 2014 and 2013.

Fair value measurements at December 31, 2012

using

Description

Total

Quoted

Significant

Total

Fair Value

Prices in

Other

unobservable

Losses

Active

Observable

Inputs

Markets for

Inputs (Level 2)

(Level 3)

Identical

Assets

(Level 1)

Prepaid land lease payment

1,226

—

1,226

—

Plant, building and equipment

1,786

—

1,786

—

2,171

Total nonrecurring

3,012

—

3,012

—

2,171

(w)Concentration of Risks

Exchange Rate Risks

The Company operates in China, which may give rise to significant foreign currency risks from fluctuations and the degree of volatility of foreign exchange rates between the US$ and the RMB. In 2014, foreign exchange loss of $647 is included in selling, general and administrative expenses (2013 - $650, 2012 - $207). As at December 31, 2014, cash and cash equivalents of $72,104 (RMB 447 million) is denominated in RMB and are held in PRC and Hong Kong (December 31, 2013 - $ 92,861 (RMB 563 million)).

Currency Convertibility Risks

Substantially all of the Company’s operating activities are transacted in RMB, which is not freely convertible into foreign currencies. All foreign exchange transactions take place either through the People’s Bank of China or other banks authorized to buy and sell foreign currencies at the exchange rates quoted by the People’s Bank of China. Approval of foreign currency payments by the People’s Bank of China or other regulatory institutions requires submitting a payment application form together with other information such as suppliers’ invoices, shipping documents and signed contracts.

Concentration of Credit Risks

Financial instruments that potentially subject the Company to concentration of credit risks consist primarily of cash and cash equivalents and accounts receivable, the balances of which are stated on the consolidated balance sheets which represent the Company’s maximum exposure. The Company places its cash and cash equivalents in good credit quality financial institutions in Hong Kong and China. Concentration of credit risks with respect to accounts receivables is linked to the concentration of revenue. The Company’s customers are mainly various government agencies in China. No single customer accounted for more than 10% of total sales for the years ended December 31, 2014, 2013 and 2012 except for government stockpile purchases revenue recognized in 2013. To manage credit risk, the Company performs ongoing credit evaluations of customers’ financial condition.

Interest Rate Risks

The Company is subject to interest rate risk. Other than a long-term loan with carrying value of $1,803 and loan from a non-controlling shareholder of $2,595 with fixed interest rates as at December 31, 2014, other interest-bearing loans are stated at variable rates based on the People’s Bank of China (note 10).

(x)Comparative information

Certain comparative figures of prior year have been reclassified to conform to the current year’s presentation.

(y)Recently Issued Accounting Standards

In May 2014, the FASB issued ASU No. 2014-09 (“ASU 2014-09”), Revenue from Contracts with Customers (Topic 606). Where a single, global revenue recognition model applies to most contracts with customers. Revenue will be recognized in a manner that depicts the transfer of goods or services to customers in an amount that reflects the consideration to which an entity expects to be entitled, subject to certain limitations. The guidance is effective for annual periods beginning after December 15, 2016. Early adoption is prohibited, and a full or modified retrospective transition method is required. The Company is currently evaluating the impact of its consolidated financial statements of adopting this standard.

In August 2014, the FASB issued ASU No. 2014-15 (“ASU 2014-15”), Going concern. Management the Company will be required to evaluate whether there is substantial doubt about the Company’s ability to continue as a going concern and, if so, disclose that fact. Management will also be required to evaluate and disclose whether its plans alleviate that doubt. The guidance is effective for annual periods beginning after December 15, 2016. Early adoption is permitted. The Company will adopt ASC 2014-15 on January 1, 2017, and does not expect the adoption of this standard will have a material impact on its consolidated financial statements.

Accounts_Receivable_net

Accounts Receivable - net	12 Months Ended
	Dec. 31, 2014
Accounts Receivable - net
Accounts Receivable - net
	3.Accounts Receivable - net

		December 31,			December 31,
		2014			2013
	Trade receivables (note 9)	$	42,423		$	33,743
	Allowance for doubtful accounts	(2,571		)	(2,429		)
		39,852			31,314
	Other receivables	905			613
	Total	$	40,757		$	31,927

	Accounts receivables with a carrying value of $5,641 (RMB 35 million) were pledged as collateral for a bank loan (note 9).

	The allowance for doubtful accounts reflects the Company’s best estimate of probable losses inherent in the accounts receivable balance. The Company estimates the allowance based on known troubled accounts, historical experience, the age of the accounts receivable balances, credit quality of the Company’s customers, current economic conditions, and other factors that may affect customers’ ability to pay. The Company records its allowance for doubtful accounts based upon its assessment of various factors. As of December 31, 2014, the Company provided 100% (December 31, 2013 -100%) allowance for accounts receivable aged more than three years, approximately 56.3% (December 31,2013 - 56.3%) allowance for accounts receivable aged between two year and three years, approximately 18.5% (December 31,2013 - 16.9%) allowance for accounts receivable aged between one year and two years, and approximately 1.8% (December 31,2013 - 1.7%) allowance for accounts receivable aged less than one year.

	The Company’s maximum exposure to credit risk at the balance sheets date relating to trade receivables is summarized as follows:

		December 31,			December 31,
		2014			2013
	Aging within one year, net of allowance for doubtful accounts	$	35,130		$	29,565

	Aging greater than one year, net of allowance for doubtful accounts	4,722			1,749
	Total	$	39,852		$	31,314

Inventories

Inventories	12 Months Ended
	Dec. 31, 2014
Inventories
Inventories
	4.Inventories

		December 31,		December 31,
		2014		2013
	Raw materials	$	2,688	$	3,832
	Work in progress	4,056		448
	Finished goods	12,088		10,049
	Total	$	18,832	$	14,329

	For the year ended December 31, 2014, the Company charged $2,492 of excessive fixed production overhead to cost of sales as such costs were incurred (2013 - $2,217, 2012- $3,140).

	For the year ended December 31, 2014, the cost of sales includes $1,273 of inventory provision for products that are likely to be expired before being sold (2013 - $1,399, 2012- $3,479).

Longterm_Inventories

Long-term Inventories	12 Months Ended
	Dec. 31, 2014
Long-term Inventories
Long-term Inventories
	5.Long-term Inventories

		December 31,		December 31,
		2014		2013
	Work in progress	$	—	$	666
	Finished goods	2,648		2,115
	Total	$	2,648	$	2,781

	Long-term inventories represent H5N1 vaccines with remaining shelf lives over one year and not expected to be sold within one year. These vaccines are for government stockpiling purposes.

Property_Plant_and_Equipment

Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment
Property, Plant and Equipment
	6.Property, Plant and Equipment

		December 31,		December 31,
		2014		2013
	Cost
	Construction in progress	$	8,206	$	424
	Plant and buildings	34,419		35,259
	Machinery and equipment	42,517		42,851
	Motor vehicles	1,832		1,884
	Equipment and furniture	2,612		2,620
	Leasehold improvements	13,232		12,386
	Total cost	$	102,818	$	95,424

	Less: Accumulated depreciation
	Construction in progress	$	—	$	—
	Plant and buildings	7,908		6,455
	Machinery and equipment	18,891		15,658
	Motor vehicles	1,643		1,653
	Equipment and furniture	1,765		1,546
	Leasehold improvements	4,194		2,149
	Total accumulated depreciation	$	34,401	$	27,461

	Property, plant and equipment net	$	68,417	$	67,963

	The buildings of the Changping facilities of Sinovac Beijing with a net book value of $14,876 (RMB 92.3 million) were pledged as collateral for a bank loan from China Construction Bank (note 9).

	The buildings of Sinovac Beijing with a net book value of $2,933 (RMB 18.2 million) was pledged as collateral for a bank loan from Bank of Beijing (note 9).

	The buildings of Sinovac Dalian with a net book value of $5,836 (RMB 36.2 million) were pledged as collateral for a bank loan from Bank of China (note 9).

	Depreciation expense for the year ended December 31, 2014 was $7,771 (2013 - $5,998, 2012 - $3,961).

	Loss on disposal of equipment for the year ended December 31, 2014 was $74 (2013 - $31, 2012 - $14).

	In 2012, Sinovac Beijing decided to move the packaging line from its Shangdi site to the Changping site. The equipment not being relocated to Changping and the leasehold improvements for the packaging line production area at the Shangdi site were impaired as a consequence. The Company recorded an impairment charge of $nil for the year ended December 31, 2014 (2013 - $57 (RMB 0.3 million), 2012 - $656 (RMB 4.1 million)).

	Tangshan Yian incurred a loss in 2012 and was expected to continue to incur losses in the future. In 2012, the Company performed a recoverability test of Tangshan Yian’s property, plant and equipment by comparing the forecasted undiscounted cash flow to be generated from continuous use of the property, plant and equipment to their carrying value. As the undiscounted cash flows over the remaining useful life of the assets were negative, the Company measured the impairment amount by estimating the fair value of the property, plant and equipment. The Company determined the fair value of Tangshan Yian’s prepaid land lease payments and plant and buildings using the market approach by obtaining quoted prices for similar assets in the principal resale market. The Company determined the fair value of Tangshan Yian’s machinery and equipment using the cost approach by estimating the amount that currently would be required to construct or purchase substitute machinery and equipment of comparable utility. The estimate considered the condition of the assets which include the physical deterioration and economic obsolescence.

	It was determined the fair value of Tangshan Yian’s property, plant and equipment and prepaid land lease payments was $2,923 compared to the carrying value of $4,420 as at December 31, 2012. As the fair value of the prepaid land lease payments exceeded their carrying value, the impairment of $1,497 was allocated on a pro-rata basis to the plant and buildings, and machinery and equipment based on their relative carrying value. At the end of 2013 and 2014, the Company determined impairment indicators at Tangshan Yian continued to exist due to losses incurred, and performed impairment analysis using the same methodology used in 2012. The Company concluded no further impairment losses were required to be recorded.

Prepaid_land_lease_payments

Prepaid land lease payments (Land use rights)	12 Months Ended
	Dec. 31, 2014
Land use rights
Prepaid land lease payments
Prepaid land lease payments
	7.Prepaid land lease payments

		December 31,		December 31,
		2014		2013

	Prepaid land lease payments	$	11,940	$	12,238
	Less: accumulated amortization	1,535		1,290
	Net carrying value	$	10,405	$	10,948

	The prepaid land lease payments of the Changping facilities of Sinovac Beijing with a net book value of $2,922 (RMB18.1 million) were pledged as collateral (note 9) for a bank loan from China Construction Bank.

	The prepaid land lease payments of Sinovac Beijing with a net book value of $352 (RMB2.2million) were pledged as collateral (note 9) for a bank loan from Bank of Beijing.

	The prepaid land lease payments of Sinovac Dalian with a net book value of $3,801 (RMB23.6million) were pledged as collateral (note 9) for a bank loan from Bank of China.

	Amortization expenses for prepaid land lease payments for the year ended December 2014 was $278 (2013 - $311, 2012 - $299).

Licenses

Licenses (Licenses)	12 Months Ended
Licenses (Licenses)	Dec. 31, 2014
Licenses
Licenses
Licenses
	8.Licenses

			December 31, 2014
					Accumulated		Net book
			Cost		amortization		value
	Inactivated hepatitis A		$	3,405	$	3,405	$	—
	Combined inactivated hepatitis A&B		490		490		—
	H5N1 licenses (note 22(c))		1,482		1,130		352
	Total		$	5,377	$	5,025	$	352

			December 31, 2013
					Accumulated		Net book
			Cost		amortization		value
	Inactivated hepatitis A		$	3,490	$	3,490	$	—
	Combined inactivated hepatitis A&B		502		452		50
	H5N1 licenses (note 22(c))		1,519		797		722
	Total		$	5,511	$	4,739	$	772

		(a)		On August 15, 2011, the Company entered into a non-exclusive main license agreement together with three sublicense agreements with Medimmune, LLC (“Medimmune”) to use patented reverse genetics technology pertaining to virus strain production for vaccines, including the H5N1 influenza virus strain. The Company amortized the patent fee on a straight-line method basis over the estimated useful life of 20 years. On August 15, 2012, the Company entered into amendment agreements with Medimmune which amended the term of the license agreements. As for the main license agreement, the estimated useful life of the patent was revised to end on December 29, 2015. The other three sublicense agreements have been revised to end on April 5, 2020, July 14, 2020, and May 23, 2021, respectively. Accordingly, the estimated useful life of the patent was revised to end on December 29, 2015 (note 22(c)) which is the termination date of the main license agreement.

		(b)		Amortization expense for the licenses was $371 for the year ended December 31, 2014 (2013 - $435, 2012 - $228).

		(c)		Estimated amortization expense for the existing license over their remaining useful lives as of December 31, 2014 is $352 within one year.

	The amortization expense forecast is an estimate. Actual amounts of amortization expense may differ from estimated amounts due to additional intangible asset acquisitions, changes in foreign currency exchange rates, impairment of licenses and other events.

Bank_loans_and_other_debt

Bank loans and other debt	12 Months Ended
	Dec. 31, 2014
Bank loans and other debt [Abstract]
Bank Loans and Other Debt
	9.Bank loans and other debt

	Summarized below were bank loans and other debt as of December 31, 2014 and 2013:

		December 31,
		2014		2013
	China Merchants Bank(a)	$	4,835	$	1,652
	Bank of Beijing (b)	8,059		—
	Bank of China (c)	1,612		1,652
	Industrial and Commercial Bank of China (d)	3,223		—

	Bank loans less than one year	17,729		3,304

	China Construction Bank (e)	13,861		330
	China Construction Bank (f)	4,044		518
	Bank of Beijing (g)	11,741		12,065

	Current portion of long-term bank loans	29,646		12,913

	China Construction Bank (e)	—		14,206
	China Construction Bank (f)	—		4,145
	Bank of Beijing (g)	—		12,065
	Beijing Zhongguancun Development Group (h)	1,803		1,730

	Long-term bank loans and other debt	1,803		32,146

	Total bank loans and other debt	$	49,178	$	48,363

	(a) In 2013, Sinovac Beijing entered into a bank loan with China Merchants Bank in the aggregate principal amount of $1,652 (RMB 10 million), bearing interest at 10% above the prime rate of a one-year term loan published by the People’s Bank of China. Interest is payable quarterly. The loan was drawn on January 31, 2013 and was repaid in full on January 30, 2014.

	In 2014, Sinovac Beijing entered into a bank loan with China Merchants Bank in the aggregate principal amount of $4,835 (RMB 30 million) to finance its working capital requirements, bearing interest at 15% above the prime rate of a one-year term loan published by the People’s Bank of China, at 6.9% per year. Interest is payable quarterly. The loan was drawn on March 3, 2014 and was repaid on March 2, 2015.

	(b) In 2014, Sinovac Beijing entered into a bank loan with Bank of Beijing in the aggregate principal amount of $8,059 (RMB 50 million) to finance its working capital requirements. The loan bears interest at 6% and is payable quarterly. The loan was drawn on August 21, 2014 and is repayable on August 21, 2015.

	(c) On December 17, 2012, Sinovac Dalian entered into a bank loan agreement with Bank of China with a credit line of $3,223 (RMB 20 million). The first $806 (RMB 5 million) was drawn down on March 13, 2013 and repaid on March 12, 2014. The second $806 (RMB 5 million) was drawn down on September 24, 2013 and repaid on September 23, 2014. The third $806 (RMB 5 million) was drawn down on March 31, 2014 and was repaid on March 26, 2015. The fourth $806 (RMB 5 million) was drawn down on September 23, 2014 and is repayable on September 22, 2015. The loan bears interest at 7.4% and the interest is payable monthly. Prepaid land lease payments and buildings of Sinovac Dalian with a net book value of $9,637 (RMB 59.8 million) were pledged as collateral.

	(d) In 2014, Sinovac Beijing entered into a bank loan with Industrial and Commercial Bank of China Limited in the aggregate principal amount of $3,223 (RMB 20 million) to finance the working capital requirements, bearing interest at 10% above the prime rate of a one-year term loan published by the People’s Bank of China plus 0.9% of financing fee per year, at 7.5% per year. Interest is payable monthly. The loan was drawn on June 19, 2014 and is repayable on June 19, 2015. The loan is guaranteed by an unrelated third party, with a guarantee fee of $64 (RMB 0.4 million) over the term of the loan. Trade receivables of Sinovac Beijing with a carrying value of not lower than $5,641 (RMB 35 million) were pledged as collateral.

	(e) The loan from China Construction Bank in the aggregate principal amount of $14,183 (RMB 88 million) (December 31, 2013 - $14,536) is exclusively for the purchase of the Changping facility, bearing interest at the bank’s prime lending rate and adjusted every 12 months, at 6.4% per year. Interest is payable monthly. Prepaid land lease payment and buildings of the Changping facilities of Sinovac Beijing with a net book value of $17,798 (RMB 110 million) were pledged as collateral. $322 (RMB 2 million) was repaid in 2013, $322 (RMB 2 million) was repaid in 2014 and $13,861 (RMB 86 million) was repaid in February 2015.

	(f) The total amount of the loan facility from China Construction Bank is $8,059 (RMB 50 million) for a three-year period from December 13, 2012 to December 12, 2015. The amount drawn is $4,996 (RMB 31 million) as at December 31, 2014. The interest is set at the bank’s prime lending rate at 6.15% per year. The loan is to be used exclusively for the operation and production costs of Sinovac Beijing. Interest is payable monthly. The loan is unsecured and 10% of the principal amount is repayable in 2013, 10% of the principal amount is repayable in 2014 with the remaining principal repayable in 2015. $458 (RMB 3 million) was repaid in 2013 and $494 (RMB 3 million) was repaid in 2014. Pursuant to the covenants set out in the agreement, the debt to total assets ratio must not be higher than 85%, the current ratio must not be lower than 1, contingent liabilities must not be higher than $14,667 (RMB 91 million) and contingent liabilities as a percentage of total shareholders’ equity must not be higher than 10%. The Company is in compliance with such covenants as of December 31, 2014 and 2013.

	(g) The loan from Bank of Beijing in the aggregate principal amount of $23,531 (RMB 146 million) (December 31, 2013- $24,130) for a period from May, 2011 to November, 2015 is for construction of the Changping facility and has a maximum credit facility amount of $32,234 (RMB 200 million). The loan bears interest at the bank’s prime lending rate and adjusted every 12 months, currently at 6.4% per year. Interest is payable quarterly. The loan is repayable in four equal installments on May 13, 2014, November 13, 2014, May 13, 2015 and November 13, 2015. $11,790 (RMB 72.6 million) was repaid in 2014. The Company also obtained a credit line with a maximum quota for issuing letter of credits of $12,894 (RMB 80 million) with the same bank. No letters of credit were issued by the Company as at December 31, 2014 and 2013, respectively. Prepaid land lease payments and buildings of Sinovac Beijing with a net book value of $3,285 (RMB 20.4 million) were pledged as collateral. $11,741 (RMB 72.9 million) is repayable in 2015.

	(h) The loan from Beijing Zhongguancun Development Group in the aggregate principal amount of $1,934 (RMB 12 million) bearing interest currently at 0.36% per year is for the purpose of funding EV71 vaccine research project of Sinovac Beijing. The total loan is $1,934 (RMB 12 million) of which $967 (RMB 6 million) was received in 2012 and the second $967 (RMB 6 million) was received in 2013. The loan is unsecured and repayable on February 24, 2016. The Beijing Zhongguancun Development Group is entitled to 10.62% ownership of the profits, if any, generated from the intellectual property developed during the loan period. No profit-sharing payments are required to be made as no profits have been generated to date. The Company can repay the loan at any time during the loan period. The fair value differential of $376 (between the face value and the fair value using the effective interest rate method at the Company’s borrowing rate of 6.9%) is recorded as non-current deferred government grant (2013 - $383) (see note 14).

	Aggregate annual principal payments of loans payable as of December 31, 2014 are as follows:

	Within 1 year	$	47,375
	Between 1 and 2 years	1,803
	Total	$	49,178

	The weighted average effective interest rate for all short-term and loan-term bank loans was 6.8% in 2014 (2013 - 6.6%, 2012 - 7.0%). The weighted average interest rate for short-term loans was 6.8% in 2014 (2013 - 7.0%, 2012 - 7.0%).The Company incurred $3,374 in interest and financing expenses for the year ended December 31, 2014 (2013 - $2,942, 2012 - $1,955), of which $nil for the year ended December 31, 2014, was capitalized in property, plant and equipment (2013 - $116, 2012 - $1,306 (net of $1,458 loan interest subsidies received)).

Related_Party_Transactions_and

Related Party Transactions and Balances	12 Months Ended
	Dec. 31, 2014
Related Party Transactions and Balances
Related Party Transactions and Balances
	10.Related Party Transactions and Balances

	(a)Loan from a non-controlling shareholder

		December 31,		December 31,
		2014		2013

	Loan - current	$	2,595	$	3,324

	The Company has a loan due to Dalian Jin Gang Group, the non-controlling shareholder of Sinovac Dalian, which is unsecured, bearing interest at 7.2% per year. Interest expense was $221 in 2014 (2013 - $237, 2012 - $231). Interest is payable monthly. As of December 31, 2014, $16 of interest payable is included in loan from a non-controlling shareholder (December 31, 2013 - $20). $649 (RMB 4 million) was repaid on September 25, 2014 and no payments were made for the years ended December 31, 2013 and 2012.

	(b)The Company entered into the following transactions in the normal course of operations at the exchange amount with related parties:

		For the year ended December 31,
		2014		2013		2012
	Rent expenses payable to SinoBioway Biotech Group Co. Ltd. (“SinoBioway”).	$	869	$	847	$	823

	In 2004, the Company entered into two operating lease agreements with SinoBioway, the non-controlling shareholder of Sinovac Beijing, with respect to Sinovac Beijing’s production plant and laboratory in Beijing, China with annual lease payments totaling $220 (RMB 1.4 million). The leases commenced on August 12, 2004 and have a term of 20 years. One of the lease agreements was amended on August 12, 2010 with the rent increasing from $81 (RMB 0.5 million) to $220 (RMB 1.4 million) per year.

	In June 2007, the Company entered into another operating lease agreement with SinoBioway, with respect to the expansion of Sinovac Beijing’s production plant in Beijing, China for an annual lease payment of $332 (RMB2.0 million). The lease commenced in June 2007 and has a term of 20 years.

	In September 2010, the Company entered into another operating lease agreement with SinoBioway with respect to expansion of Sinovac R&D’s business on research and development for an annual lease payment of $164 (RMB 1.0 million). The lease commenced on September 30, 2010 and has a term of five years.

	On April 8, 2013, the Company entered into three supplemental agreements with SinoBioway, under which the expiration date of three of the four operating lease agreements was extended to April 7, 2033.

	Included in current and long-term prepaid expenses and deposits as at December 31, 2014, is $389 (RMB 2.4 million) (December 31, 2013 -$306 (RMB 1.9 million)), representing prepaid lease payments made to this related party.

Accounts_Payable_and_Accrued_L

Accounts Payable and Accrued Liabilities	12 Months Ended
	Dec. 31, 2014
Accounts Payable and Accrued Liabilities
Accounts Payable and Accrued Liabilities
	11.Accounts Payable and Accrued Liabilities

		December 31, 2014		December 31, 2013
	Trade payables	$	3,164	$	6,063
	Machinery and equipment payables	2,209		2,270
	Accrued expenses	8,342		8,669
	Value added tax payable	206		208
	Other tax payable	177		576
	Withholding tax payable	354		1,511
	Bonus and benefit payables	5,626		5,244
	Other payables	3,159		3,496
	Total	$	23,237	$	28,037

Income_Taxes

Income Taxes	12 Months Ended
Income Taxes	Dec. 31, 2014
Income Taxes
Income Taxes
	12.Income Taxes

	Antigua and Barbuda

	Under the current laws of Antigua and Barbuda, the Company is not subject to tax on income or capital gains. Additionally, upon payments of dividends by the Company to its shareholders, no Antigua and Barbuda withholding tax will be imposed.

	Hong Kong

	Under the Hong Kong tax laws, Sinovac Hong Kong is exempted from income tax on its foreign-derived income and there are no withholding taxes in Hong Kong on remittance of dividends.

	China

	Effective from January 1, 2008, the PRC’s statutory income tax rate is 25%.The Company’s PRC subsidiaries are subject to income tax at the statutory rate of 25% except for Sinovac Beijing. Sinovac Beijing, being reconfirmed as a “High and New Technology Enterprise” (“HNTE”) in 2014 for a period of 3 years, is subject to a preferential income tax rate of 15% from 2014 to 2016.

	The Company’s income (loss) before income tax consists of:

			For the year ended December 31,
			2014			2013			2012

	Non-PRC		$	(1,336	)	$	(65	)	$	(527	)
	PRC		2,458			8,210			(19,106		)
	Total		$	1,122		$	8,145		$	(19,633	)

	Income taxes are attributed to the operations in China and consist of:

			For the year ended December 31,
			2014			2013			2012

	Current		$	(1,620	)	$	—		$	867
	Deferred		162			2,225			17
	Total income tax benefit (expense)		$	(1,458	)	$	2,225		$	884

	The following is a reconciliation of the Company’s total income tax benefit (expense) to the amount computed by applying the PRC statutory income tax rate of 25% to its income (loss) before income taxes for the years ended December 31, 2014, 2013 and 2012:

			For the year ended December 31,
			2014			2013			2012
	Income (loss) before income tax expense and non-controlling interests		$	1,122		$	8,145		$	(19,633	)
	Income tax (expense) benefit at the PRC statutory rate		(281		)	(2,036		)	4,909
	International tax rate differential		(334		)	(16		)	(40		)
	Change in unrecognized tax benefits		(282		)	(25		)	147
	Other adjustments		(79		)	228			59
	Permanent differences		362			412			904
	Effect of preferential tax treatment		901			1,573			(648		)
	Change in valuation allowance		(1,639		)	2,089			(5,314		)
	Effect of PRC withholding tax		(106		)	—			867
	Income tax benefit (expense)		$	(1,458	)	$	2,225		$	884

	The tax effects of temporary differences that give rise to the Company’s deferred tax assets are as follows:

			December 31,
			2014			2013
	Accrued expenses		$	2,413		$	1,982
	Inventories		388			729
	Prepaid expenses and deposits		(6		)	—
	Deferred government grants		12			—
	Tax losses carried forward		—			485
	Less: valuation allowance		(541		)	(594		)
	Deferred tax assets, current portion		$	2,266		$	2,602

	Fixed assets		1,493			576
	Deferred government grants		428			—
	Tax losses carried forward		10,805			10,060
	Less: valuation allowance		$	(12,211	)	$	(10,519	)
Deferred tax assets,non-current portion		$	515		$	117

In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which the temporary differences become deductible or utilized. The Company considers projected future taxable income and tax planning strategies in making this assessment. Based upon an assessment of the level of historical taxable income and projections for future taxable income over the periods in which the deferred tax assets are deductible or can be utilized, the Company provided valuation allowance of $12,752 as of December 31, 2014 ( December 31, 2013 - $11,113).

The Company evaluates its valuation allowance requirements at end of each reporting period by reviewing all available evidence, both positive and negative, and considering whether, based on the weight of that evidence, a valuation allowance is needed. When circumstances cause a change in management’s judgement about the realizability of deferred tax assets, the impact of the change on the valuation allowance is generally reflected in income from operations. The future realization of the tax benefit of an existing deductible temporary difference ultimately depends on the existence of sufficient taxable income of the appropriate character within the carry forward period available under applicable tax law.

Tax losses of the Company’s PRC subsidiaries in the amount of $43,221 (RMB 262 million) as of December 31, 2014 and will expire from 2015 to 2019.

As of December 31, 2014, the Company has not recognized any deferred tax liability on Sinovac Beijing’s undistributed earnings of approximately $5,420, in view of the Company’s permanent reinvestment plan. The Company would be subject to PRC withholding income taxes at 5% or 10%, depending on the availability of treaty benefit between China and Hong Kong, upon the distribution of such profits outside of China. As of December 31, 2014, the amount of unrecognized deferred tax liability ranges from $271 to $542.

The changes in unrecognized tax benefits are as follows:

		For the year ended December 31,
		2014			2013			2012
Balance at January 1		$	370		$	345		$	198
Additions for tax positions of the current year		168			25			147
Lapse of statute of limitations		(56		)	—			—
Balance at December 31		$	482		$	370		$	345

The Company recognizes interest and penalties, if any, related to unrecognized tax benefits as part of its income tax expenses. The Company did not record any interest and penalties as of December 31, 2014 (December 31, 2013 - $nil, December 31, 2012 - $nil).The PRC tax law provides statute of limitations ranging from 3 to 10 years. The PRC tax returns for the Company’s PRC subsidiaries are open to examination by tax authorities for the tax years beginning in 2004.

As of December 31, 2014, the Company had unrecognized tax benefits of approximately $482 (December 31, 2013 - $370, December 31, 2012 - $345) and such balance was included in “other non-current liabilities”. All of the unrecognized tax benefits would affect the effective tax rate if recognized. In February 2015, a local taxing authority initiated a tax audit on one of the Company’s PRC subsidiaries for the year ended December 31, 2013. The local taxing authority raised some queries on the deductibility of certain expenses of the concerned subsidiary and management was in the process of clarifying the natures of those expenses and hence their tax deductibility with the taxing authority. The potential tax exposures for 2013 and 2012 were $208 and $153, respectively. No unrecognized tax benefits were accrued on these potential tax exposures before as management considered it was more likely than not that these expenses were income tax deductible. The reasonable possible change on the Company’s unrecognized tax benefits in the next 12 months ranges from $nil to $361.

Deferred_Revenue

Deferred Revenue	12 Months Ended
Deferred Revenue	Dec. 31, 2014
Deferred Revenue
Deferred Revenue
	13.Deferred Revenue

	Current deferred revenue included $3,546 received from the Chinese government for stockpiling of H5N1 vaccines (December 31, 2013 - $102) that expire within one year and $1,450 of advances from customers (December 31, 2013 - $773).

	Long-term deferred revenue included $7,191 received from the Chinese government for stockpiling of H5N1 vaccines (December 31, 2013 - $11,005).

Deferred_Government_Grants

Deferred Government Grants	12 Months Ended
Deferred Government Grants	Dec. 31, 2014
Deferred Government Grants
Deferred Government Grants
	14.Deferred Government Grants

	Deferred government grants represent funding received from the government for R&D, or investment in building or improving production facility. The amount of deferred government grants as at year end is net of research and development expenditures or depreciation incurred or those recognized as government grant income. The Company received $3,520 (RMB 21.7 million) in 2014 (2013 - $842 (RMB 5.2 million, 2012 - $936 (RMB 5.9 million)).

	Deferred government grants included $1,466 (RMB 9.1 million) represents the unamortized portion of the amount that the Company received in 2007 for construction of a pandemic influenza vaccine plant and buildings of RMB 20 million (December 31, 2013 - $1,800 (RMB 10.9 million)). $290 (RMB 1.8 million) which will be amortized in 2015 was included in the current portion and $1,176 (RMB 7.3 million) which will be amortized after 2015 was included in the non-current portion of the deferred government grants. The production facility grant requires the Company to have the entire facility available to manufacture pandemic influenza vaccines at any given moment upon request by the Chinese government. The Company has fulfilled the conditions attached to the government grant. Government grant relating to these production facilities of $290, $237 and $285 for the years ended December 31, 2014, 2013 and 2012, respectively, was recorded as a reduction to the related depreciation expenses.

	Deferred government grants also included $630 (RMB 3.9 million) being the unamortized portion of the amount that the Company received in 2009 for purchasing equipment for H1N1 vaccine production with a total amount of $999 (RMB 6.2 million). The amount of $143 (RMB 0.9 million) which will be recognized in 2015 was included in the current portion and the amount of $487 (RMB 3.0 million) which will be recognized after 2015 was included in the non-current portion of deferred government grants. The Company has fulfilled the conditions attached to the government grant. Government grants relating to the production facility of $143, $119 and $82 for the years ended December 31, 2014, 2013 and 2012, respectively, were recorded as a reduction to the related depreciation expenses.

	Deferred government grants also included $81 (RMB 0.5 million) being the unamortized portion of the amount that the Company received in 2013 for purchasing equipment for H5N1 vaccine production. The amount of $16 (RMB 0.1 million) which will be amortized in 2015 was included in the current portion and the amount of $65 (RMB 0.4 million) which will be amortized after 2015 was included in the non-current portion of deferred government grants. Government grant relating to this production facility of $16 for the year ended December 31, 2014 was recorded as a reduction to the related depreciation expenses.

	The Company received a government grant in the amount of $3,223 (RMB 20 million) for equipment purchase and construction of the EV71 vaccine production facility. As of December 31, 2014, the Company has not fulfilled the conditions attached to the government grant. As the Company does not expect to fulfill the conditions within one year, the grant is recorded as a non-current government grant.

	Deferred government grants also include $1,525 (RMB 9.5 million) that the Company received for research and development, as well as purchasing equipment for EV71 vaccine production. As of December 31, 2014, the Company has not fulfilled the conditions attached to the government grant. As the Company does not expect to fulfill the conditions within one year, the grant is recorded as a non-current government grant.

	Deferred government grants also include $723 (RMB 4.5 million) in relation to four other research projects. As of December 31, 2014, the conditions attached to three government grants totalling $642 (RMB 4 million) has not been fulfilled by the Company. As the Company does not expect to fulfill the conditions within one year, these grants are recorded as non-current deferred government grants (December 31, 2013 - $578 (RMB 3.6 million)). The Company expects to fulfil the conditions attached to one of the four grants and recorded $81 (RMB 0.5 million) as a current government grant (December 31, 2013 - $83 (RMB 0.5 million) in non-current government grant).

	The Company received a loan of $1,934 (RMB 12million) bearing an interest rate of 0.36% per year from Beijing Zhongguancun Development Group. The fair value differential (between the face value and the fair value using the effective interest rate method at the Company’s borrowing rate of 6.9%) is recorded as non-current deferred government grant of $376 (December 31, 2013 - $383) (see note 9).

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies
Commitments and Contingencies
	15.Commitments and Contingencies

	(a)Operating Lease Commitments

	The Company leases production plant and laboratory under operating leases from its related parties (note 10 (b)). Rental expense amounted to $869 for the year ended December 31, 2014 (2013 - $847, 2012 - $823).

	Minimum future rental payments under operating leases to related parties for the years ending December 31 are as follows:

	2015	$	869
	2016	869
	2017	869
	2018	869
	2019	869
	Thereafter	9,679
	Total minimum future payments	$	14,024

	(b)Other Commitments

	In addition to commitments disclosed in note 22, commitments related to R&D expenditures are $960 as at December 31, 2014.

	Commitments related to capital expenditures for the Company’s pneumococcal polysaccharide and varicella vaccine production facilities are approximately $5,528 as at December 31, 2014.

Common_Stock

Common Stock	12 Months Ended
Common Stock	Dec. 31, 2014
Common Stock.
Common Stock
	16.Common Stock

	Share Capital

	Each share of common stock is entitled to one vote per share and is entitled to dividends when declared by the Company’s board of directors. As of December 31, 2014 and 2013, there were 55,809,661 and 55,570,361 shares of common stock outstanding, respectively. As of December 31, 2014 and 2013, there was no preferred stock issued and outstanding.

	In 2012, the Company issued 317,600 shares of common stock on the exercise of employee stock options with exercise price of $1.60 per share, for total proceeds of $508. The Company received further cash proceeds of $8 on the exercise of stock option for which the shares were issued subsequent to December 31, 2012.

	In 2013, the Company issued 360,600 shares of common stock on the exercise of employee stock options with exercise price of $1.60 per share and 118,200 shares of common stock on the exercise of employee stock options with exercise price of $2.37 per share, for total proceeds of $848. The Company received further cash proceeds of $18 on the exercise of stock option for which the shares were issued subsequent to December 31, 2013.

	In 2014, the Company issued 48,000 shares of common stock on the exercise of employee stock options with exercise price of $1.60 per share and 191,300 shares of common stock on the exercise of employee stock options with exercise price of $2.37 per share, for total proceeds of $512. The Company received further cash proceeds of $51 on the exercise of stock option for which the shares were issued subsequent to December 31, 2014.

Stock_Options

Stock Options	12 Months Ended
Stock Options	Dec. 31, 2014
Stock Options
Stock Options
	17.Stock Options

	(a)Stock Option Plan

	The board of directors approved a stock option plan (the “2003 Plan”) effective on November 1, 2003, pursuant to which directors, officers, employees and consultants of the Company are eligible to receive grants of options for the Company’s common stock. The 2003 Plan expires on November 1, 2023. Up to 10% of the Company’s then outstanding common stocks were reserved for issuance under the 2003 Plan. As of December 31, 2014, 42,800 shares of common stock under the 2003 Plan remain available for issuance. Each stock option entitles its holder to purchase one share of common stock of the Company. Options may be granted for a term not exceeding 10 years from the date of grant. The 2003 Plan is administered by the board of directors.

	In December 2011, the Company granted 767,000 options to employees with an exercise price of $2.37, being the quoted market price of the Company’s shares at the time of grant. 10% of the options vest every three months from December 26, 2012 to March 26, 2015 and expire on December 25, 2017.

	On May 1, 2012, the Company granted 50,000 options to an officer with an exercise price of $2.05, being the quoted market price of the Company’s shares at the time of grant. The options were granted on May 1, 2012 and expire on April 30, 2017. 10% of the options will vest on May 1, 2013 (the “Initial Vesting Date”) and the remaining options will vest at 10% in equal quarterly proportions over a period of 27 months from the Initial Vesting Date. The officer has left the Company at the end of May 2013 and forfeited the unvested options in June 2013.

	On August 22, 2012, the board of directors approved a new stock option plan (the “2012 Plan”), which allowed the Company to issue up to 4,000,000 options for common shares of the Company to directors, officers, employees and consultants of the Company. Each stock option entitles its holder to purchase one share of common stock of the Company. Options may be granted for a term not exceeding 10 years from the date of grant. The 2012 Plan is administered by the board of directors. No stock options were granted under the 2012 Plan as of December 31, 2014. The 2012 Plan will expire on August 22, 2022. Any awards that are outstanding on August 22, 2022 will remain in force according to the terms of the 2012 Plan and the applicable award agreement.

	(b)Valuation Assumptions

	The following assumptions were used in determining stock based compensation costs under the Black-Scholes option-pricing model:

			2014		2013		2012
	Expected volatility		—		—		82.89	%
	Risk-free interest rate		—		—		0.39	%
	Expected life (years)		—		—		2.95
	Dividend yield		—		—		Nil
	Estimated forfeiture rate		—		—		10	%

	The weighted average fair value of options granted for the year ended December 31, 2014 was $nil per option (2013 - $nil, 2012 - $1.08).

	Expected volatility is estimated based on the Company’s historical stock prices. Computation of expected life was estimated after considering the contractual terms of the stock-based award, vesting schedules and expectations of future employee behaviour. The risk-free interest rates for the period within the contractual life of the awards are based on the U.S. Treasury yield in effect at the time of grant.

	(c)Stock-based Payment Award Activity

	A summary of the Company’s stock options activity for the 2003 Plan is presented below:

					Weighted			Aggregate Intrinsic
					Average			Aggregate Intrinsic
			Number		Exercise Price			Value
			of Options		($/option)			($)
	Outstanding as at December 31, 2013		904,400		$	2.14		$	3,603,712
	Granted		—
	Exercised		(239,300	)	2.22			—
	Forfeited		(27,900	)	2.37			—
	Outstanding as at December 31, 2014		637,200		$	2.09		$	1,997,644

	Vested and expected to vest at December 31, 2014		596,240		$	2.08		$	1,880,498
	Exercisable as at December 31, 2014		560,550		$	2.06		$	1,778,282

	As at December 31,2014

	Exercise			Number of		Remaining Average		Average		Number	Remaining	Average Exercise
	Exercise			Number of		Remaining Average		Exercise		of	Contractual	Average Exercise
	Prices			Options		Contractual		Price		Options	Life	Price
	($/option)			Outstanding		Life (years)		($/option)		Exercisable	(years)	($/option)
	$	1.60		227,600		0.05		$	1.60	227,600	0.05	$	1.60
	$	2.37		409,600		2.99		$	2.37	332,900	2.99	$	2.37
				637,200		1.94				560,500	1.80	$	2.06

	Stock-based compensation expense, included in selling, general and administrative expenses, is charged to operations over the vesting period of the options using the straight-line amortization method. The share-based compensation expense was $287 in 2014 (2013 - $281, 2012 - $347). As of December 31, 2014, there was $175 of unrecognized compensation cost related to non-vested stock options and granted under the 2003 Plan and this cost will be recognized over a period of 3 months.

	The aggregate intrinsic value of the Company’s stock options is calculated as the difference between the exercise price of the options and the quoted price of the common shares that were in the money. The aggregate intrinsic value of the Company’s stock options exercised under the 2003 Plan was $840 for year ended December 31, 2014, determined as of the date of option exercise (2013 - $1,344, 2012 - $127).

	The estimated fair value of stock options vested during the year ended December 31, 2014 was $414 (2013 - $420, 2012 - $631).

Statutory_surplus_reserves

Statutory surplus reserves	12 Months Ended
Statutory surplus reserves	Dec. 31, 2014
Statutory surplus reserves.
Statutory surplus reserves
	18.Statutory surplus reserves

	Pursuant to Chinese company law applicable to foreign investment companies, the Company’s PRC subsidiaries are required to maintain statutory surplus reserves. The statutory surplus reserves are to be appropriated from net income after taxes, and should be at least 10% of the after tax net income determined in accordance with accounting principles and relevant financial regulations applicable to PRC enterprises (“PRC GAAP”). The Company has an option of not appropriating the statutory surplus reserve after the statutory surplus reserve is equal to 50% of the subsidiary’s registered capital. Statutory surplus reserves are recorded as a component of shareholders’ equity. The statutory surplus reserve as at December 31, 2014 is $12,627 (2013 - $11,808).

	For the year ended December 31, 2014, Sinovac Beijing appropriated 10 % ( 2013 - 0%, 2012 - 0%) of its after-tax profit, determined under PRC GAAP, to the statutory surplus reserves. For the year ended December 31, 2014, statutory surplus reserves appropriated are $819 (RMB 5 million) (2013 - $nil, 2012- $nil).

	Pursuant to the same Chinese company law, the Company’s subsidiaries, Sinovac Beijing, Tangshan Yian, Sinovac R&D and Sinovac Dalian can transfer, at the discretion of their respective boards of directors, a certain amount of their annual net income after taxes as determined under PRC GAAP to a staff welfare and bonus fund which shall be utilized for collective staff benefits. For the year ended December 31, 2014, the amount is $nil for contribution to such fund (2013 - $nil, 2012- $nil). The amounts appropriated to the staff welfare and bonus fund were charged against income and the related provisions were reflected as accrued liabilities in the consolidated balance sheets.

	Tangshan Yian recorded a net loss for each of the three years in the period ended December 31, 2014, so no appropriation to the statutory surplus reserves and staff welfare and bonus fund was made.

	Sinovac R&D and Sinovac Dalian have not made any profit since inception. No appropriation to the statutory surplus reserves and staff welfare and bonus was made.

	Dividends declared by the Company’s PRC subsidiaries are based on the distributable profits as reported in their statutory financial statements reported in accordance with PRC GAAP, which differ from the results of operations reflected in the consolidated financial statements prepared in accordance with US GAAP. The Company’s ability to pay dividends is primarily dependent on the Company receiving distributions of funds from its PRC subsidiaries. Dividends declared in 2014 was $nil to the non-controlling shareholder of Sinovac Beijing (2013 - $nil, 2012 - $802 (RMB5 million)). As of December 31, 2014, the Company has $nil dividend payable (December 31, 2013 - $nil).

	Under PRC laws and regulations, statutory surplus reserves are restricted to set-off against losses, expansion of production and operation and increasing registered capital of the respective company, and are not distributable other than upon liquidation. Staff welfare and bonus funds are restricted to expenditures for the collective welfare of employees. The reserves are not allowed to be transferred to the Company in terms of cash dividends, loans or advances, nor are they allowed for distribution except under liquidation. Amounts restricted include the PRC subsidiaries’ paid-in capital and statutory surplus reserves of the Company’s PRC subsidiaries totalling $80,091(RMB 497 million) as of December 31, 2014 (December 31, 2013, $81,249 (RMB492 million)). Further, foreign exchange and other regulations in the PRC further restrict the Company’s PRC subsidiaries from transferring funds to the Company in the form of loans, advances or cash dividends. As of December 31, 2014, amount restricted include the net assets of the Company’s PRC subsidiaries, which amounted to $61,345 (December 31, 2013 - $34,860).

Noncontrolling_Interests

Non-controlling Interests	12 Months Ended
Non-controlling Interests	Dec. 31, 2014
Non-controlling Interests.
Non-controlling Interests
	19.Non-controlling Interests

	Non-controlling interests represent the interest of non-controlling shareholders in Sinovac Beijing and Sinovac Dalian based on their proportionate interests in the equity of that company adjusted for its proportionate share of income or losses from operations. On October 1, 2011, the Company increased its ownership in Sinovac Beijing by an additional 1.53% by contributing the dividends declared to Sinovac Hong Kong but unpaid in the amount of $2,998 (RMB 18.6 million). An adjustment of $258 (RMB 1.6 million) resulted from the difference between the adjustment to the carrying amount of the non-controlling interest in Sinovac Beijing and the consideration that was charged to additional paid-in capital.The non-controlling interest in Sinovac Beijing was 28.44% prior to October 1, 2011 and was 26.91% after October 1, 2011. On April 8, 2013, SinoBioway transferred its 26.91% equity interests in Sinovac Beijing to Xiamen Bioway Biotech Co., Ltd. (“Xiamen Bioway”), a company owned by SinoBioway. There was no change to the composition of the board of directors of Sinovac Beijing after the completion of the transaction. The non-controlling interest in Sinovac Dalian was 45% as of December 31, 2014 and December 31, 2013.

Earnings_loss_per_Share

Earnings (loss) per Share	12 Months Ended
	Dec. 31, 2014
Earnings (loss) per Share
Earnings (loss) per Share
	20.Earnings (loss) per Share

	Earnings (loss) per share were calculated as follows:

		For the year ended December 31
		2014			2013		2012
	Net income (loss) attributable to shareholders	$	(851	)	$	7,442	$	(14,853	)

	Basic weighted average number of common shares outstanding	55,681,076			55,301,276		54,926,440

	Effect of dilutive securities:
	Stock options	—			501,062		—
	Diluted weighted average number of common shares outstanding	55,681,076			55,802,338		54,926,440
	Basic earnings (loss) per share	$	(0.02	)	$	0.13	$	(0.27	)
	Diluted earnings (loss) per share	$	(0.02	)	$	0.13	$	(0.27	)

	Anti-dilutive options were not included in the diluted EPS calculation for the years ended December 31, 2014 and December 31, 2012.

Segmented_Information

Segmented Information	12 Months Ended
Segmented Information	Dec. 31, 2014
Segmented Information
Segmented Information
	21.Segmented Information

	The Company operates exclusively in the biotechnology sector. The Company’s business is considered as operating in one segment. The Company’s Chief Executive Officer is the chief operating decision maker and reviews the consolidated results of operations when making decisions about resources allocation and assessing performance of the Company as a whole. All revenues are generated from the subsidiaries located in China. Total long-lived assets of $79,174 including prepaid land lease payments, property, plant and equipment and licenses are all located in mainland China (December 31, 2013 - $79,683). The Company’s total assets by geographic location are as follows:

		December 31, 2014		December 31, 2013
	Assets
	Mainland China	$	207,645	$	199,703
	Hong Kong	30,885		40,990
	Total	$	238,530	$	240,693

	The Company’s revenues by product are as follows:

		For the year ended December 31,
		2014		2013		2012
	Sales
	Inactivated hepatitis vaccines	$	48,450	$	47,202	$	39,951
	Influenza vaccines	12,131		12,156		9,191
	H5N1	201		10,736		—
	Mumps	2,150		1,680		24
	Rabend	169		750		50
	Total	$	63,101	$	72,524	$	49,216

	The H5N1 vaccines were all sold to the Chinese government. The Company’s sales of H5N1 vaccines are dependent on government stockpiling purchases. Loss of such government stockpiling purchases would have a material adverse effect on the Company’s total sales.

	The Company’s revenues are attributed to geographic locations as follows:

		For the year ended December 31,
		2014		2013		2012
	Sales
	Mainland China	$	62,124	$	71,397	$	48,199
	Foreign countries	977		1,127		1,017
	Total	$	63,101	$	72,524	$	49,216

Collaboration_Agreements

Collaboration Agreements	12 Months Ended
Collaboration Agreements	Dec. 31, 2014
Collaboration Agreements
Collaboration Agreements
	22.Collaboration Agreements

	(a) On March 12, 2009, the Company entered into a technology transfer agreement (with an amendment agreement entered on December 14, 2011) with Tianjin CanSino Biotechnology Inc. (“Tianjin Cansino”). According to the agreement, Tianjing Cansino will transfer the technology related to pneumococcal vaccine to the Company and jointly develop the technology with the Company. The collaboration term under the technology transfer agreement is from March 12, 2009 to eight years after the first sale of the vaccine developed under the technology transfer agreement in the Chinese market.

	Under the terms of the technology transfer agreement, the Company will make milestone payments of up to $3,000 and royalty payments ranging from 6% to 10% of net sales in China. Both parties will work together to develop international markets for the products. On November 17, 2009 and December 14, 2011, two amendment agreements were signed for the payment of $300 for the transfer of an additional six serotypes and related technology. As of December 31, 2014, the Company made total milestone payments of $1,200 ($1,000 under the March 12, 2009 agreement and $200 under the December 14, 2011 amendment). The remaining milestone payment will be paid when the Company achieves each specific milestone, which includes obtaining clinical trials approval, completing clinical trials and achievement of desired results, and achievement of commercial sales. The Company recorded $nil R&D expenses for the year ended December 31, 2014 (2013 - $nil, 2012 - $200).

	On January 29, 2015, the Company entered into a third amendment to the technology transfer agreement dated March 12, 2009 and the two amendment agreements dated November 17, 2009 and December 24, 2011. By entering into this third amendment, the technology transfer agreement was revised to be a licensing agreement. The remaining milestone and royalty payments under the technology transfer agreement have been reduced. Both the Company and Tianjin Cansino are free to develop pneumococcal vaccines or to collaborate with one other company for the same purpose. The Company made a payment of $300 in March 2015.

	(b)On August 18, 2009, the Company entered into a patent license agreement with the National Institutes of Health (“NIH”), an agency of the United States Public Health Services within the Department of Health and Human Services. NIH has granted the Company a non-exclusive license to make and use certain of its products. NIH has also granted the Company the right to use certain associated information for development of its licensed products. The collaboration term under the patent license agreement is from August 18, 2009 to the later of (a) the expiration of all royalty obligations under the licensed rights where such rights exist and (b) eight years after the first commercial sale by the Company, unless the agreement is terminated earlier per the provisions included therein.

	The Company has agreed to pay NIH a license issue royalty of $80 upon execution of the agreement and a non-refundable minimum annual royalty of $8, and royalty payments on net sales ranging from 1.5% to 4% depending on the sales territory and the customers. The Company has also agreed to pay NIH benchmark royalties of $330 upon achieving each benchmark as specified in the patent license agreement, including completion of clinical trials, obtaining regulatory approval for marketing, and achievement of commercial sales.The Company recorded a license issue royalty of $8 for the year ended December 31, 2014 as R&D expenses (2013 - $21, 2012 - $8).

	(c)On August 15, 2011, the Company licensed from Medimmune, LLC, a US based pharmaceutical company, certain non-exclusive rights to use patented reverse genetics technology pertaining toH5N1 influenza virus strain production for vaccines. The Company has agreed to pay an upfront license fee and milestone payments of up to an aggregate of $9.9 million based upon achievement of cumulative net sales of licensed products in China (including Hong Kong and Macau), as well as royalty payments in single digit of net sales of the licensed products in China (including Hong Kong and Macau). License fee and royalties of $3,400 accrued at the end of 2011 were paid in 2012. In 2013, the Company obtained a new stockpile order of 3 million doses H5N1 vaccines from the Chinese government. For the year ended December 31, 2013, royalties of $1,036 was capitalized as inventory costs and included in accounts payable and accrued liabilities, which was paid in May 2014. No royalties were incurred for the year ended December 31,2014.

	On August 15, 2012, the Company entered into amendment agreements with Medimmune to revise the termination date of the license to December 29, 2015 as a result of amendment of the main license agreement to end on December 29, 2015. The other three sublicense agreements have been revised to end on April 5, 2020, July 14, 2020, and May 23, 2021, respectively.

	(d)On April 3, 2014, the Company entered into a non-exclusive license agreement (the “Agreement”) with The Institute for Translational Vaccinology (“INTRAVACC”), a governmental institute working under the Dutch Ministry of Public Health, Welfare and Sports, to develop and commercialize the Sabin Inactivated Polio Vaccine (“sIPV”) for distribution in China and other countries. The Company expects to develop and commercialize the vaccine in China, as well as seeking regulatory approval in other countries. The agreement has a term of 50 years.

	The Company has agreed to pay INTRAVACC up to net of PRC tax $2,406 (€1.5 million), including an entrance fee and milestone payments upon achieving specific milestones. The Company has also agreed to pay royalty payments in single digit on net sales generated worldwide from the product or products developed under the Agreement. The Company recorded an entrance fee of $665 (€0.5 million) for the year ended December 31, 2014 as research and development expense. The Company also recorded $125 (€94) for payment made to INTRAVACC for use of sIPV viral seeds in research and development expense, for the year ended December 31, 2014.

Subsequent_Events

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2014
Subsequent Events.
Subsequent Events
	23.Subsequent Events

	In February 2015, Sinovac Beijing repaid a loan in an aggregate principal amount of $13,861 (RMB 86 million) to China Construction Bank.

	In March 2015, Sinovac Beijing repaid a one year term loan in an aggregate principal amount of $4,835 (RMB 30 million) to China Merchants Bank.

	In March 2015, Sinovac Dalian repaid a loan in an aggregate principal amount of $806 (RMB 5 million) to Bank of China.

	In February 2015, the Beijing Municipal Office of the State Administration of Taxation (“SAT”) commenced a tax audit of Sinovac Beijing for the 2013 tax year, the results of which are pending. The tax exposure has been disclosed in note 12.

Condensed_Financial_Informatio

Condensed Financial Information of the Parent Company	12 Months Ended
Condensed Financial Information of the Parent Company	Dec. 31, 2014
Condensed Financial Information of the Parent Company
Condensed Financial Information of the Parent Company
	24. Condensed Financial Information of the Parent Company

	Balance Sheets

			December 31,			December 31,
			2014			2013
	ASSETS

	Current assets
	Cash and cash equivalents		$	997		$	1,400
	Prepaid expenses and other receivables		9			123
	Amount due from subsidiaries		69,824			68,520
	Dividend receivables		21,280			21,280

	Total current assets		92,110			91,323

	Investment in subsidiaries		38,616			40,044

	Total assets		$	130,726		$	131,367

	LIABILITIES AND EQUITY

	Current liabilities
	Accrued expenses and other payables		$	584		$	920
	Amount due to subsidiaries		3,578			1,763

	Total current liabilities		4,162			2,683

	Total liabilities		4,162			2,683

	EQUITY
	Preferred stock		—			—
	Authorized 50,000,000 shares at par value of $0.001 each Issued and outstanding: nil
	Common stock		56			56
	Authorized: 100,000,000 shares at par value of $0.001 each Issued and outstanding: 55,809,661 (2013—55,570,361)
	Additional paid-in capital		108,243			107,393
	Accumulated other comprehensive income		12,022			14,141
	Accumulated deficit		6,243			7,094

	Total shareholders’ equity		126,564			128,684

	Total liabilities and equity		$	130,726		$	131,367

	Statements of Comprehensive Income (Loss)

			For the year ended December 31
			2014			2013			2012
	Operation expenses

	General and administrative expenses		$	2,466		$	2,710		$	3,170

	Total operating expenses		2,466			2,710			3,170

	Loss from operations		(2,466		)	(2,710		)	(3,170		)

	Interest income		759			755			879

	Equity income (losses) of subsidiaries, net of tax		856			9,397			(12,562		)

	Net income (loss)		(851		)	7,442			(14,853		)

	Other comprehensive income (loss), net of tax of nil
	Foreign currency translation adjustments		(2,119		)	2,370			1,793

Total comprehensive income (loss)		$	(2,970	)	$	9,812		$	(13,060	)

Statements of Cash Flows

		For the year ended December 31
		2014			2013			2012
Cash flows provided by (used in) operating activities
Net income (loss)		$	(851	)	$	7,442		$	(14,853	)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
- Stock-based compensation		287			281			347
- Equity in earnings (loss) of subsidiaries		(856		)	(9,397		)	12,562
Changes in:
- Amount due from subsidiaries		(1,304		)	2,505			(1,283		)
- Prepaid expenses and other receivables		114			59			25
- Dividend receivables		—			1,043			(13,782		)
- Amount due to subsidiaries		1,815			1,130			(1,792		)
- Accrued expenses and other payables		(336		)	(776		)	269

Net cash provided by (used in) operating activities		(1,131		)	2,287			(18,507		)

Cash flows provided by financing activities
- Proceeds from issuance of common stock, net of share issuance costs		512			848			508
- Proceeds from shares subscribed		51			18			8

Net cash provided by financing activities		563			866			516

Cash flows provided by (used in) investing activities
-Investment in subsidiaries		165			(4,042		)	16,588

Net cash provided by (used in) investing activities		165			(4,042		)	16,588

Decrease in cash and cash equivalents		(403		)	(889		)	(1,403		)

Cash and cash equivalents, beginning of year		1,400			2,289			3,692

Cash and cash equivalents, end of year		$	997		$	1,400		$	2,289

(a) Basis of presentation

The condensed financial information has been prepared using the same accounting policies as set out in the accompanying consolidated financial statements except that the Company used the equity method to account for investment in its subsidiaries.

The Company records its investment in its subsidiaries under the equity method of accounting. Such investment is presented on the balance sheets as “Investment in subsidiaries” and share of their income (loss) as “Equity income (losses) of subsidiaries” in the statements of comprehensive income (loss).

Each of the Company’s PRC subsidiaries has restrictions on its ability to pay dividends to the Company under PRC laws and regulations (Note 18). The subsidiaries did not pay any dividends to the Company for the years presented.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted by reference to the consolidated financial statements.

(b) Commitments

The Company does not have any significant commitments or long-term obligations as of any of the periods presented, except for those disclosed in the consolidated financial statements (notes 15 and 22).

Significant_Accounting_Policie1

Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2014

Significant Accounting Policies

Use of Estimates

(a)Use of Estimates

Cash and Cash Equivalents

(b)Cash and Cash Equivalents

Cash equivalents consist of highly liquid investments that are readily convertible to cash generally with maturities of three months or less when purchased.

Accounts Receivable

(c)Accounts Receivable

Inventories

(d)Inventories

Property, Plant and Equipment

(e)Property, Plant and Equipment

Depreciation of property, plant and equipment is computed using the straight-line method based on the estimated useful lives of the assets as follows:

Plant and buildings

10 to 24 years

Machinery and equipment

8 to 10 years

Motor vehicles

4 to 5 years

Office equipment and furniture

3 to 5 years

Leasehold improvements

Lesser of useful lives and term of lease

Prepaid land lease payments

(f)Prepaid land lease payments

Licenses

(g)Licenses

Impairment of Long-Lived Assets

(h)Impairment of Long-Lived Assets

Income Taxes

(i)Income Taxes

Value-added Taxes

(j)Value-added Taxes

Revenue Recognition

(k)Revenue Recognition

Shipping and Handling

(l)Shipping and Handling

Advertising Expenses

(m)Advertising Expenses

Advertising costs are expensed as incurred and included in selling, general and administrative expenses. Advertising costs were $268 for the year ended December 31, 2014 (2013 - $474, 2012 - $29).

Research and Development

(n)Research and Development

Government Grants

(o)Government Grants

Retirement and Other Post-retirement Benefits

(p)Retirement and Other Post-retirement Benefits

Foreign Currency Translation and Transactions

(q)Foreign Currency Translation and Transactions

Stock-based Compensation

(r)Stock-based Compensation

Comprehensive Income (loss)

(s)Comprehensive Income (loss)

The Company’s comprehensive income (loss) consists of net income (loss) and foreign currency translation adjustments.

Earnings (loss) Per Share

(t)Earnings(loss) Per Share

Operating Lease

(u)Operating Leases

Fair Value of Measurements

(v)Fair Value Measurements

Level 1 — Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 3 — Unobservable inputs for the asset or liability.

As of December 31, 2014 and 2013, the Company did not have any financial assets or liabilities measured at fair value on a recurring basis.

Fair value measurements at December 31, 2012

using

Description

Total

Quoted

Significant

Total

Fair Value

Prices in

Other

unobservable

Losses

Active

Observable

Inputs

Markets for

Inputs (Level 2)

(Level 3)

Identical

Assets

(Level 1)

Prepaid land lease payment

1,226

—

1,226

—

Plant, building and equipment

1,786

—

1,786

—

2,171

Total nonrecurring

3,012

—

3,012

—

2,171

Exchange Rate Risks

Currency Convertibility Risks

Concentration of Credit Risks

Interest Rate Risks

Comparative information

(x)Comparative information

Certain comparative figures of prior year have been reclassified to conform to the current year’s presentation.

Recently Adopted and issued Accounting Standards

(y)Recently Issued Accounting Standards

Basis_of_Presentation_Tables

Basis of Presentation (Tables)	12 Months Ended
Basis of Presentation (Tables)	Dec. 31, 2014
Basis of Presentation
Schedule of details of the Company's subsidiaries

	Name	Date of	Place of	Percentage of	Percentage of	Principal activities
		incorporation or	incorporation	ownership as	ownership as of
		establishment	(or	of December	December 31, 2013
			establishment)	31, 2014
			/operation
	Sinovac Biotech (Hong Kong) Ltd (“Sinovac Hong Kong”)	Oct-08	Hong Kong	100%	100%	Investment holding company

	Sinovac Biotech Co., Ltd. (“Sinovac Beijing”) (note 19)	Apr-01	People’s Republic of China (“PRC”)	73.09%	73.09%	Research and development, production and sales of vaccine products

	Tangshan Yian Biological Engineering Co., Ltd. (“Tangshan Yian”)	Feb-93	PRC	100%	100%	Research and development, production and sales of vaccine products

	Sinovac Biological Technology Co., Ltd. (“Sinovac R&D”)	May-09	PRC	100%	100%	Research and development of vaccine products

	Sinovac (Dalian) Vaccine Technology Co., Ltd. (“Sinovac Dalian”) (note19)	Jan-10	PRC	55%	55%	Research and development, production and sales of vaccine products

Significant_Accounting_Policie2

Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2014

Significant Accounting Policies

Schedule of estimated useful lives of assets included in property, plant and equipment

Plant and buildings

10 to 24 years

Machinery and equipment

8 to 10 years

Motor vehicles

4 to 5 years

Office equipment and furniture

3 to 5 years

Leasehold improvements

Lesser of useful lives and term of lease

Schedule of fair value of equipment and leasehold improvement using the market approach by obtaining quoted prices for similar assets in the principal resale market

Fair value measurements at December 31, 2012

using

Description

Total

Quoted

Significant

Total

Fair Value

Prices in

Other

unobservable

Losses

Active

Observable

Inputs

Markets for

Inputs (Level 2)

(Level 3)

Identical

Assets

(Level 1)

Prepaid land lease payment

1,226

—

1,226

—

Plant, building and equipment

1,786

—

1,786

—

2,171

Total nonrecurring

3,012

—

3,012

—

2,171

Accounts_Receivable_net_Tables

Accounts Receivable - net (Tables)	12 Months Ended
	Dec. 31, 2014
Accounts Receivable - net
Schedule of accounts receivable - net

		December 31,			December 31,
		2014			2013
	Trade receivables (note 9)	$	42,423		$	33,743
	Allowance for doubtful accounts	(2,571		)	(2,429		)
		39,852			31,314
	Other receivables	905			613
	Total	$	40,757		$	31,927


Schedule of maximum exposure to credit risk at the balance sheet date relating to trade receivables

		December 31,			December 31,
		2014			2013
	Aging within one year, net of allowance for doubtful accounts	$	35,130		$	29,565

	Aging greater than one year, net of allowance for doubtful accounts	4,722			1,749
	Total	$	39,852		$	31,314

Inventories_Tables

Inventories (Tables)	12 Months Ended
	Dec. 31, 2014
Inventories
Schedule of inventories

		December 31,		December 31,
		2014		2013
	Raw materials	$	2,688	$	3,832
	Work in progress	4,056		448
	Finished goods	12,088		10,049
	Total	$	18,832	$	14,329

Longterm_Inventories_Tables

Long-term Inventories (Tables)	12 Months Ended
	Dec. 31, 2014
Long-term Inventories
Schedule of long-term inventories

		December 31,		December 31,
		2014		2013
	Work in progress	$	—	$	666
	Finished goods	2,648		2,115
	Total	$	2,648	$	2,781

Property_Plant_and_Equipment_T

Property, Plant and Equipment (Tables)	12 Months Ended
Property, Plant and Equipment (Tables)	Dec. 31, 2014
Property, Plant and Equipment
Schedule of property, plant and equipment

		December 31,		December 31,
		2014		2013
	Cost
	Construction in progress	$	8,206	$	424
	Plant and buildings	34,419		35,259
	Machinery and equipment	42,517		42,851
	Motor vehicles	1,832		1,884
	Equipment and furniture	2,612		2,620
	Leasehold improvements	13,232		12,386
	Total cost	$	102,818	$	95,424

	Less: Accumulated depreciation
	Construction in progress	$	—	$	—
	Plant and buildings	7,908		6,455
	Machinery and equipment	18,891		15,658
	Motor vehicles	1,643		1,653
	Equipment and furniture	1,765		1,546
	Leasehold improvements	4,194		2,149
	Total accumulated depreciation	$	34,401	$	27,461

	Property, plant and equipment net	$	68,417	$	67,963

Prepaid_land_lease_payments_Ta

Prepaid land lease payments (Tables) (Land use rights)	12 Months Ended
	Dec. 31, 2014
Land use rights
Prepaid land lease payments
Schedule of prepaid land lease payments

		December 31,		December 31,
		2014		2013

	Prepaid land lease payments	$	11,940	$	12,238
	Less: accumulated amortization	1,535		1,290
	Net carrying value	$	10,405	$	10,948

Licenses_Tables

Licenses (Tables) (Licenses)	12 Months Ended
Licenses (Tables) (Licenses)	Dec. 31, 2014
Licenses
Licenses
Schedule of licenses

			December 31, 2014
					Accumulated		Net book
			Cost		amortization		value
	Inactivated hepatitis A		$	3,405	$	3,405	$	—
	Combined inactivated hepatitis A&B		490		490		—
	H5N1 licenses (note 22(c))		1,482		1,130		352
	Total		$	5,377	$	5,025	$	352

			December 31, 2013
					Accumulated		Net book
			Cost		amortization		value
	Inactivated hepatitis A		$	3,490	$	3,490	$	—
	Combined inactivated hepatitis A&B		502		452		50
	H5N1 licenses (note 22(c))		1,519		797		722
	Total		$	5,511	$	4,739	$	772

		(a)		On August 15, 2011, the Company entered into a non-exclusive main license agreement together with three sublicense agreements with Medimmune, LLC (“Medimmune”) to use patented reverse genetics technology pertaining to virus strain production for vaccines, including the H5N1 influenza virus strain. The Company amortized the patent fee on a straight-line method basis over the estimated useful life of 20 years. On August 15, 2012, the Company entered into amendment agreements with Medimmune which amended the term of the license agreements. As for the main license agreement, the estimated useful life of the patent was revised to end on December 29, 2015. The other three sublicense agreements have been revised to end on April 5, 2020, July 14, 2020, and May 23, 2021, respectively. Accordingly, the estimated useful life of the patent was revised to end on December 29, 2015 (note 22(c)) which is the termination date of the main license agreement.

		(b)		Amortization expense for the licenses was $371 for the year ended December 31, 2014 (2013 - $435, 2012 - $228).

		(c)		Estimated amortization expense for the existing license over their remaining useful lives as of December 31, 2014 is $352 within one year.

Bank_loans_and_other_debt_Tabl

Bank loans and other debt (Tables)	12 Months Ended
	Dec. 31, 2014
Bank loans and other debt [Abstract]
Schedule of Bank Loans and Other Debt

		December 31,
		2014		2013
	China Merchants Bank(a)	$	4,835	$	1,652
	Bank of Beijing (b)	8,059		—
	Bank of China (c)	1,612		1,652
	Industrial and Commercial Bank of China (d)	3,223		—

	Bank loans less than one year	17,729		3,304

	China Construction Bank (e)	13,861		330
	China Construction Bank (f)	4,044		518
	Bank of Beijing (g)	11,741		12,065

	Current portion of long-term bank loans	29,646		12,913

	China Construction Bank (e)	—		14,206
	China Construction Bank (f)	—		4,145
	Bank of Beijing (g)	—		12,065
	Beijing Zhongguancun Development Group (h)	1,803		1,730

	Long-term bank loans and other debt	1,803		32,146

	Total bank loans and other debt	$	49,178	$	48,363


Schedule of aggregate annual principal payments of loans payable
	Aggregate annual principal payments of loans payable as of December 31, 2014 are as follows:

	Within 1 year	$	47,375
	Between 1 and 2 years	1,803
	Total	$	49,178

Related_Party_Transactions_and1

Related Party Transactions and Balances (Tables)	12 Months Ended
	Dec. 31, 2014
Related Party Transactions and Balances
Schedule of loan from a non-controlling shareholder

		December 31,		December 31,
		2014		2013

	Loan - current	$	2,595	$	3,324


Schedule of transactions in the normal course of operations at the exchange amount with related parties

		For the year ended December 31,
		2014		2013		2012
	Rent expenses payable to SinoBioway Biotech Group Co. Ltd. (“SinoBioway”).	$	869	$	847	$	823

Accounts_Payable_and_Accrued_L1

Accounts Payable and Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2014
Accounts Payable and Accrued Liabilities
Schedule of accounts payable and accrued liabilities

		December 31, 2014		December 31, 2013
	Trade payables	$	3,164	$	6,063
	Machinery and equipment payables	2,209		2,270
	Accrued expenses	8,342		8,669
	Value added tax payable	206		208
	Other tax payable	177		576
	Withholding tax payable	354		1,511
	Bonus and benefit payables	5,626		5,244
	Other payables	3,159		3,496
	Total	$	23,237	$	28,037

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2014
Income Taxes
Schedule of income (loss) before income tax

		For the year ended December 31,
		2014			2013			2012

	Non-PRC	$	(1,336	)	$	(65	)	$	(527	)
	PRC	2,458			8,210			(19,106		)
	Total	$	1,122		$	8,145		$	(19,633	)


Schedule of income taxes attributed to the operations in China

		For the year ended December 31,
		2014			2013			2012

	Current	$	(1,620	)	$	—		$	867
	Deferred	162			2,225			17
	Total income tax benefit (expense)	$	(1,458	)	$	2,225		$	884


Reconciliation of income taxes at the statutory income tax rate in Antigua and Barbuda to income tax rate based on income before income taxes stated in the consolidated statements of comprehensive income (loss)

		For the year ended December 31,
		2014			2013			2012
	Income (loss) before income tax expense and non-controlling interests	$	1,122		$	8,145		$	(19,633	)
	Income tax (expense) benefit at the PRC statutory rate	(281		)	(2,036		)	4,909
	International tax rate differential	(334		)	(16		)	(40		)
	Change in unrecognized tax benefits	(282		)	(25		)	147
	Other adjustments	(79		)	228			59
	Permanent differences	362			412			904
	Effect of preferential tax treatment	901			1,573			(648		)
	Change in valuation allowance	(1,639		)	2,089			(5,314		)
	Effect of PRC withholding tax	(106		)	—			867
	Income tax benefit (expense)	$	(1,458	)	$	2,225		$	884


Schedule of deferred tax assets

		December 31,
		2014			2013
	Accrued expenses	$	2,413		$	1,982
	Inventories	388			729
	Prepaid expenses and deposits	(6		)	—
	Deferred government grants	12			—
	Tax losses carried forward	—			485
	Less: valuation allowance	(541		)	(594		)
	Deferred tax assets, current portion	$	2,266		$	2,602

	Fixed assets	1,493			576
	Deferred government grants	428			—
	Tax losses carried forward	10,805			10,060
	Less: valuation allowance	$	(12,211	)	$	(10,519	)
	Deferred tax assets,non-current portion	$	515		$	117


Schedule of unrecognized tax benefits

		For the year ended December 31,
		2014			2013			2012
	Balance at January 1	$	370		$	345		$	198
	Additions for tax positions of the current year	168			25			147
	Lapse of statute of limitations	(56		)	—			—
	Balance at December 31	$	482		$	370		$	345

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies
Schedule of minimum future rental payments under operating leases to related parties
	Minimum future rental payments under operating leases to related parties for the years ending December 31 are as follows:

	2015	$	869
	2016	869
	2017	869
	2018	869
	2019	869
	Thereafter	9,679
	Total minimum future payments	$	14,024

Stock_Options_Tables

Stock Options (Tables)	12 Months Ended
Stock Options (Tables)	Dec. 31, 2014
Stock Options
Schedule of assumptions used in determining stock based compensation costs under the Black-Scholes option pricing model
			2014		2013		2012
	Expected volatility		—		—		82.89	%
	Risk-free interest rate		—		—		0.39	%
	Expected life (years)		—		—		2.95
	Dividend yield		—		—		Nil
	Estimated forfeiture rate		—		—		10	%


Summary of stock options activity

					Weighted			Aggregate Intrinsic
					Average			Aggregate Intrinsic
			Number		Exercise Price			Value
			of Options		($/option)			($)
	Outstanding as at December 31, 2013		904,400		$	2.14		$	3,603,712
	Granted		—
	Exercised		(239,300	)	2.22			—
	Forfeited		(27,900	)	2.37			—
	Outstanding as at December 31, 2014		637,200		$	2.09		$	1,997,644

	Vested and expected to vest at December 31, 2014		596,240		$	2.08		$	1,880,498
	Exercisable as at December 31, 2014		560,550		$	2.06		$	1,778,282


Schedule of stock options by range of exercise prices
	As at December 31,2014

	Exercise			Number of		Remaining Average		Average		Number	Remaining	Average Exercise
	Exercise			Number of		Remaining Average		Exercise		of	Contractual	Average Exercise
	Prices			Options		Contractual		Price		Options	Life	Price
	($/option)			Outstanding		Life (years)		($/option)		Exercisable	(years)	($/option)
	$	1.60		227,600		0.05		$	1.60	227,600	0.05	$	1.60
	$	2.37		409,600		2.99		$	2.37	332,900	2.99	$	2.37
				637,200		1.94				560,500	1.80	$	2.06

Earnings_loss_per_Share_Tables

Earnings (loss) per Share (Tables)	12 Months Ended
	Dec. 31, 2014
Earnings (loss) per Share
Schedule of calculation of earnings (loss) per share

		For the year ended December 31
		2014			2013		2012
	Net income (loss) attributable to shareholders	$	(851	)	$	7,442	$	(14,853	)

	Basic weighted average number of common shares outstanding	55,681,076			55,301,276		54,926,440

	Effect of dilutive securities:
	Stock options	—			501,062		—
	Diluted weighted average number of common shares outstanding	55,681,076			55,802,338		54,926,440
	Basic earnings (loss) per share	$	(0.02	)	$	0.13	$	(0.27	)
	Diluted earnings (loss) per share	$	(0.02	)	$	0.13	$	(0.27	)

Segmented_Information_Tables

Segmented Information (Tables)	12 Months Ended
Segmented Information (Tables)	Dec. 31, 2014
Segmented Information
Schedule of Company's total assets by geographic location

		December 31, 2014		December 31, 2013
	Assets
	Mainland China	$	207,645	$	199,703
	Hong Kong	30,885		40,990
	Total	$	238,530	$	240,693


Schedule of Company's revenues by product

		For the year ended December 31,
		2014		2013		2012
	Sales
	Inactivated hepatitis vaccines	$	48,450	$	47,202	$	39,951
	Influenza vaccines	12,131		12,156		9,191
	H5N1	201		10,736		—
	Mumps	2,150		1,680		24
	Rabend	169		750		50
	Total	$	63,101	$	72,524	$	49,216


Schedule of Company's revenues attributed to geographic locations

		For the year ended December 31,
		2014		2013		2012
	Sales
	Mainland China	$	62,124	$	71,397	$	48,199
	Foreign countries	977		1,127		1,017
	Total	$	63,101	$	72,524	$	49,216

Condensed_Financial_Informatio1

Condensed Financial Information of the Parent Company (Tables)	12 Months Ended
	Dec. 31, 2014
Condensed Financial Information of the Parent Company
Balance Sheets

		December 31,			December 31,
		2014			2013
	ASSETS

	Current assets
	Cash and cash equivalents	$	997		$	1,400
	Prepaid expenses and other receivables	9			123
	Amount due from subsidiaries	69,824			68,520
	Dividend receivables	21,280			21,280

	Total current assets	92,110			91,323

	Investment in subsidiaries	38,616			40,044

	Total assets	$	130,726		$	131,367

	LIABILITIES AND EQUITY

	Current liabilities
	Accrued expenses and other payables	$	584		$	920
	Amount due to subsidiaries	3,578			1,763

	Total current liabilities	4,162			2,683

	Total liabilities	4,162			2,683

	EQUITY
	Preferred stock	—			—
	Authorized 50,000,000 shares at par value of $0.001 each Issued and outstanding: nil
	Common stock	56			56
	Authorized: 100,000,000 shares at par value of $0.001 each Issued and outstanding: 55,809,661 (2013—55,570,361)
	Additional paid-in capital	108,243			107,393
	Accumulated other comprehensive income	12,022			14,141
	Accumulated deficit	6,243			7,094

	Total shareholders’ equity	126,564			128,684

	Total liabilities and equity	$	130,726		$	131,367


Statements of Comprehensive Income (Loss)

		For the year ended December 31
		2014			2013			2012
	Operation expenses

	General and administrative expenses	$	2,466		$	2,710		$	3,170

	Total operating expenses	2,466			2,710			3,170

	Loss from operations	(2,466		)	(2,710		)	(3,170		)

	Interest income	759			755			879

	Equity income (losses) of subsidiaries, net of tax	856			9,397			(12,562		)

	Net income (loss)	(851		)	7,442			(14,853		)

	Other comprehensive income (loss), net of tax of nil
	Foreign currency translation adjustments	(2,119		)	2,370			1,793

	Total comprehensive income (loss)	$	(2,970	)	$	9,812		$	(13,060	)


Statements of Cash Flows

		For the year ended December 31
		2014			2013			2012
	Cash flows provided by (used in) operating activities
	Net income (loss)	$	(851	)	$	7,442		$	(14,853	)
	Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
	- Stock-based compensation	287			281			347
	- Equity in earnings (loss) of subsidiaries	(856		)	(9,397		)	12,562
	Changes in:
	- Amount due from subsidiaries	(1,304		)	2,505			(1,283		)
	- Prepaid expenses and other receivables	114			59			25
	- Dividend receivables	—			1,043			(13,782		)
	- Amount due to subsidiaries	1,815			1,130			(1,792		)
	- Accrued expenses and other payables	(336		)	(776		)	269

	Net cash provided by (used in) operating activities	(1,131		)	2,287			(18,507		)

	Cash flows provided by financing activities
	- Proceeds from issuance of common stock, net of share issuance costs	512			848			508
	- Proceeds from shares subscribed	51			18			8

	Net cash provided by financing activities	563			866			516

	Cash flows provided by (used in) investing activities
	-Investment in subsidiaries	165			(4,042		)	16,588

	Net cash provided by (used in) investing activities	165			(4,042		)	16,588

	Decrease in cash and cash equivalents	(403		)	(889		)	(1,403		)

	Cash and cash equivalents, beginning of year	1,400			2,289			3,692

	Cash and cash equivalents, end of year	$	997		$	1,400		$	2,289

Basis_of_Presentation_Details

Basis of Presentation (Details)	Dec. 31, 2014	Dec. 31, 2013
Sinovac Hong Kong
Basis of Presentation
Percentage of ownership	100.00%	100.00%
Sinovac Beijing
Basis of Presentation
Percentage of ownership	73.09%	73.09%
Tangshan Yian
Basis of Presentation
Percentage of ownership	100.00%	100.00%
Sinovac R&D
Basis of Presentation
Percentage of ownership	100.00%	100.00%
Sinovac Dalian
Basis of Presentation
Percentage of ownership	55.00%	55.00%

Significant_Accounting_Policie3

Significant Accounting Policies (Details)	12 Months Ended
Significant Accounting Policies (Details)	Dec. 31, 2014
Plant and building \| Minimum
Property, Plant and Equipment
Estimated useful life	10 years
Plant and building \| Maximum
Property, Plant and Equipment
Estimated useful life	24 years
Machinery and equipment \| Minimum
Property, Plant and Equipment
Estimated useful life	8 years
Machinery and equipment \| Maximum
Property, Plant and Equipment
Estimated useful life	10 years
Motor vehicles \| Minimum
Property, Plant and Equipment
Estimated useful life	4 years
Motor vehicles \| Maximum
Property, Plant and Equipment
Estimated useful life	5 years
Office equipment and furniture \| Minimum
Property, Plant and Equipment
Estimated useful life	3 years
Office equipment and furniture \| Maximum
Property, Plant and Equipment
Estimated useful life	5 years

Significant_Accounting_Policie4

Significant Accounting Policies (Details 2) (USD $)	6 Months Ended		12 Months Ended			9 Months Ended	0 Months Ended	7 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Aug. 15, 2012	Aug. 14, 2012
Impairment of long-lived assets
Impairment charges on long-lived assets			$0	$57	$2,176
Value-added Taxes
Value-added taxes rate (as a percent)	3.00%	6.00%
H5N1 licenses
Licenses
Estimated useful life						20 years
Land use rights \| Minimum
Licenses
Estimated useful life			28 years
Land use rights \| Maximum
Licenses
Estimated useful life			49 years
Licenses
Licenses
Estimated useful life			9 years 1 month 28 days
Licenses \| Inactivated hepatitis A and recombinant hepatitis A&B licenses
Licenses
Estimated useful life			10 years
Licenses \| H5N1 licenses
Licenses
Estimated useful life								20 years
Remaining useful life							3 years

Significant_Accounting_Policie5

Significant Accounting Policies (Details 3) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Shipping and Handling
Shipping and handling costs, included in selling, general and administrative expenses	$1,241	$1,235	$1,118
Advertising Expenses
Advertising costs, included in selling, general and administrative expenses	268	474	29
Retirement and other post-retirement benefits
Amount incurred	3,498	3,138	2,771
Foreign Currency Translation and Transactions
Foreign exchange gains (losses) included in selling, general and administrative expenses	-647	650	207
Gains (losses) on intra-entity foreign currency transactions that are of a long-term-investment nature	294	235	199
Operating Leases
Capital leases	0	0
Seasonal influenza vaccine
Revenue Recognition
Sales return provisions	1,320	575
Inactivated hepatitis A and recombinant hepatitis A&B licenses
Revenue Recognition
Sales return provisions	$3,553	$2,240
Sales return provision represented as a percentage of private pay market sales	8.60%	5.50%

Significant_Accounting_Policie6

Significant Accounting Policies (Details 4) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Fair Value Measurements
Property, plant and equipment, carrying value	$68,417	$67,963
Total Losses	0	57	2,176
Nonrecurring basis
Fair Value Measurements
Total nonrecurring	0	0
Total Losses			2,171
Total nonrecurring	0	0
Nonrecurring basis \| Plant, building and equipment
Fair Value Measurements
Total Losses			2,171
Nonrecurring basis \| Significant Other Observable Inputs (Level 2)
Fair Value Measurements
Total nonrecurring			3,012
Nonrecurring basis \| Significant Other Observable Inputs (Level 2) \| Land use rights
Fair Value Measurements
Total nonrecurring			1,226
Nonrecurring basis \| Significant Other Observable Inputs (Level 2) \| Plant, building and equipment
Fair Value Measurements
Total nonrecurring			1,786
Nonrecurring basis \| Fair value
Fair Value Measurements
Total nonrecurring			3,012
Nonrecurring basis \| Fair value \| Land use rights
Fair Value Measurements
Total nonrecurring			1,226
Nonrecurring basis \| Fair value \| Plant, building and equipment
Fair Value Measurements
Total nonrecurring			1,786
Tangshan Yian
Fair Value Measurements
Property, plant and equipment, fair value			2,923
Property, plant and equipment, carrying value			4,420
Sinovac Beijing \| Equipment and leasehold improvement
Fair Value Measurements
Property, plant and equipment, fair value			89
Property, plant and equipment, carrying value			$763

Significant_Accounting_Policie7

Significant Accounting Policies (Details 5)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2013
	USD ($)	USD ($)	USD ($)	USD ($)	Denominated in RMB	Denominated in RMB	Denominated in RMB	Denominated in RMB
					USD ($)	CNY	USD ($)	CNY
Exchange Rate Risks
Foreign exchange gains (losses) included in selling, general and administrative expenses	($647)	$650	$207
Cash and cash equivalents denominated in RMB	$91,518	$107,242	$91,241	$104,287	$72,104	447,000	$92,861	563,000

Significant_Accounting_Policie8

Significant Accounting Policies (Details 6) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Significant Accounting Policies
Long-term loan with fixed interest rate	$1,803
Loan from a non-controlling shareholder with fixed interest rate	$2,595	$3,324

Accounts_Receivable_net_Detail

Accounts Receivable - net (Details)

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

In Thousands, unless otherwise specified

USD ($)

CNY

USD ($)

Trade receivables

Aging within one year, net of allowance for doubtful accounts

Aging greater than one year, net of allowance for doubtful accounts

Other receivables

Accounts aged more than three years

Accounts receivable aged between two year and three years

Accounts receivable aged between one year and two years

Accounts receivable aged less than one year

USD ($)

Accounts Receivable - net

Accounts receivable, gross

$42,423

$33,743

Allowance for doubtful accounts

-2,571

-2,429

Total

40,757

31,927

39,852

31,314

35,130

29,565

4,722

1,749

905

613

Carrying value of accounts receivable pledged as collateral for a bank loan

$5,641

35,000

Percentage allowance for accounts receivable

100.00%

56.30%

18.50%

16.90%

1.80%

1.70%

Inventories_Details

Inventories (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Inventories
Raw materials	$2,688	$3,832
Work in progress	4,056	448
Finished goods	12,088	10,049
Total	18,832	14,329
Fixed production overhead charged to cost of sales	2,492	2,217	3,140
Inventory provision for products likely to be expired included in cost of sales	$1,273	$1,399	$3,479

Longterm_Inventories_Details

Long-term Inventories (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Long-term Inventories
Work in progress		$666
Finished goods	2,648	2,115
Total	$2,648	$2,781

Property_Plant_and_Equipment_D

Property, Plant and Equipment (Details)

12 Months Ended

In Thousands, unless otherwise specified

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

USD ($)

Bank Of Beijing

Sinovac Beijing

Tangshan Yian

Construction in progress

Plant and building

Machinery and equipment

Motor vehicles

Office equipment and furniture

Leasehold improvements

Building

Bank of Beijing loan for Changping facility

USD ($)

CNY

USD ($)

CNY

China Construction Bank

USD ($)

Sinovac Beijing

Sinovac Dalian

USD ($)

CNY

China Construction Bank Loan for Changping facility

China Construction Bank

Bank Of Beijing

Bank Of China

USD ($)

CNY

China Construction Bank Loan for Changping facility

Bank of Beijing loan for Changping facility

Bank of China Term loan

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

Property, Plant and Equipment

Cost

$102,818

$95,424

$8,206

$424

$34,419

$35,259

$42,517

$42,851

$1,832

$1,884

$2,612

$2,620

$13,232

$12,386

Less: Accumulated depreciation

34,401

27,461

7,908

6,455

18,891

15,658

1,643

1,653

1,765

1,546

4,194

2,149

Impairment of plant and building, and machinery and equipment

1,497

Property, plant and equipment net

68,417

67,963

4,420

Land use rights and building of subsidiary pledged as collateral

3,285

20,400

17,798,000

110,000

14,876

92,300

2,933

18,200

5,836

36,200

Depreciation expense

7,771

5,998

3,961

Loss on disposal of equipment

Impairment charge

300

656

4,100

Fair value of property, plant and equipment rights

$2,923

Prepaid_land_lease_payments_De

Prepaid land lease payments (Details)

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2014

In Thousands, unless otherwise specified

Bank Of Beijing

Land use rights

Sinovac Beijing

Sinovac Dalian

Bank of Beijing loan for Changping facility

USD ($)

China Construction Bank

Land use rights

USD ($)

CNY

China Construction Bank Loan for Changping facility

China Construction Bank

Bank Of Beijing

Bank Of China

USD ($)

CNY

China Construction Bank Loan for Changping facility

Bank of Beijing loan for Changping facility

Bank of China Term loan

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

Prepaid land lease payments

$11,940

$12,238

Accumulated amortization

1,535

1,290

Net book value

10,405

10,948

Amount pledged as collateral

3,285

20,400

17,798,000

110,000

2,922

18,100

352

2,200

3,801

23,600

Amortization expense

$278

$311

$299

Licenses_Details

Licenses (Details) (USD $)	9 Months Ended	12 Months Ended			0 Months Ended	7 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2012	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Aug. 15, 2011	Aug. 14, 2012
	Sep. 30, 2012	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	item	Aug. 14, 2012
H5N1 licenses
Licenses
Estimated useful life	20 years
Licenses
Licenses
Cost		$5,377	$5,511
Accumulated amortization		5,025	4,739
Estimated useful life		9 years 1 month 28 days
Amortization expense		371	435	228
Estimated amortization expenses
Within 1 year		352
Net book value		352	772
Licenses \| Inactivated hepatitis A
Licenses
Cost		3,405	3,490
Accumulated amortization		3,405	3,490
Licenses \| Combined inactivated hepatitis A&B
Licenses
Cost		490	502
Accumulated amortization		490	452
Estimated amortization expenses
Net book value			50
Licenses \| H5N1 licenses
Licenses
Cost		1,482	1,519
Accumulated amortization		1,130	797
Estimated useful life						20 years
Estimated amortization expenses
Net book value		$352	$722
Number of sublicense agreements entered with Medimmune					3

Bank_loans_and_other_debt_Deta

Bank loans and other debt (Details)

12 Months Ended

0 Months Ended

12 Months Ended

In Thousands, unless otherwise specified

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2014

Dec. 31, 2013

Jan. 31, 2013

Dec. 31, 2013

Dec. 31, 2014

Mar. 03, 2014

Dec. 31, 2014

Aug. 21, 2014

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Sep. 23, 2014

Mar. 31, 2014

Sep. 24, 2013

Mar. 13, 2013

Dec. 31, 2014

Dec. 31, 2013

Dec. 17, 2012

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

USD ($)

China Merchants Bank

Bank Of Beijing

Bank Of China

Industrial And Commercial Bank Of China

China Construction Bank

Beijing Zhongguancun Development Group

USD ($)

China Merchants Bank term loan drawn on January 31st 2013

Bank Term Loan Drawn In March 2014

USD ($)

Bank Term Loan Drawn In August 2014

Bank of Beijing loan for Changping facility

USD ($)

Line of Credit

USD ($)

Bank Term Loan Drawn In June 2014

China Construction Bank Loan for Changping facility

China Construction Bank - Sinovac Beijing

USD ($)

Term Loan For Funding Vaccine Research Project

Sinovac Beijing

USD ($)

CNY

USD ($)

Letter of Credit

Sinovac Dalian

Sinovac Beijing

USD ($)

Sinovac Beijing

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

Prime Rate

USD ($)

CNY

Prime Rate

USD ($)

CNY

item

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

Prime Rate

USD ($)

CNY

USD ($)

CNY

Bank Loans and Other Debt

Bank loan

$17,729

$3,304

$4,835

$1,652

$8,059

$1,612

$1,652

$3,223

Current portion of long-term bank loans

29,646

12,913

11,741

72,900

12,065

13,861

330

13,861

86,000

4,044

518

Long-term bank loans and other debt

1,803

32,146

12,065

14,206

4,145

1,803

1,730

Total bank loans and other debt

49,178

48,363

Face amount of debt instrument

1,652

10,000

4,835

30,000

8,059

50,000

3,223

20,000

8,059

50,000

1,934

12,000

Maximum borrowing capacity

32,234

200,000

12,894

80,000

3,223

20,000

Interest rate amount over base rate (as a percent)

10.00%

15.00%

10.00%

Term of debt instrument

1 year

3 years

Amount drawn/ received

17,837

16,800

16,787

806

5,000

806

5,000

806

5,000

806

5,000

967

6,000

967

6,000

Interest rate (as a percent)

6.00%

7.40%

6.15%

0.36%

Repayment of debt

15,962

4,089

4,755

11,790

72,600

322

2,000

322,000

2,000

494

3,000

458

3,000

Financing fee rate (as a percent)

0.90%

Current interest rate (as a percent)

6.80%

6.60%

7.00%

6.90%

6.40%

7.50%

6.40%

Guarantee fee

400

Amount pledged as collateral

3,285

20,400

9,637

59,800

5,641

35,000

17,798,000

110,000

Aggregate principal amount outstanding

23,531

146,000

24,130

14,183

88,000

14,536

4,996

31,000

Percentage of debt repayable

10.00%

Debt covenant, debt to total assets ratio not higher than

85.00%

Debt covenant, current ratio not lower than

1.00%

Debt covenant, contingent liability not higher than

14,667

91,000

Debt covenant, gearing ratio not higher than

10.00%

Term after which variable rate basis is to be adjusted

12 months

Number of installments in which loan is repayable

Letters of credit issued

Ownership of profits from intellectual property, percentage to which lender is entitled

10.62%

Fair value differential

376

383

Effective interest rate used to calculate fair value differential (as a percent)

6.90%

Aggregate annual principal payments of loans payable

Within 1 year

47,375

16,217

Between 1 and 2 years

1,803

Total bank loans and other debt

49,178

48,363

Weighted average interest rate for short-term loans

6.80%

7.00%

Interest costs incurred, net of interest subsidies received

3,374

2,942

1,955

Interest costs capitalized in property, plant and equipment

116

1,306

Interest subsidies received

$1,458

Related_Party_Transactions_and2

Related Party Transactions and Balances (Details)

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

In Thousands, unless otherwise specified

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Sep. 25, 2014

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Apr. 08, 2013

Aug. 12, 2010

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2014

Dec. 31, 2013

Aug. 12, 2004

Dec. 31, 2004

Aug. 12, 2010

Jun. 30, 2007

Sep. 30, 2010

USD ($)

Dalian Jin Gang Group

Sino Bioway

USD ($)

CNY

USD ($)

item

USD ($)

CNY

Two operating lease agreements, production plant and laboratory

Before amendment, one operating lease agreement, production plant and laboratory

After amendment, one operating lease agreement, production plant and laboratory

Operating lease agreement, expansion of production plant and laboratory

Operating lease agreement, R&D expansion

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

item

Related Party Transactions and Balances

Loan - current

$2,595

$3,324

Interest rate on loan from related party (as a percent)

7.20%

Interest expense

221

237

231

221

237

231

Amount of interest payable included in loan from a non-controlling shareholder

Repayment of loan to related party

649

4,000

Expense payable to related party

869

847

823

Number of operating lease agreements entered with related party

Operating lease, annual rent

220

1,400

500

220

1,400

332

2,000

164

1,000

Term of lease

20 years

5 years

Number of lease agreements amended

Number of supplemental agreements entered into with the related party

Number of operating lease agreements for which expiration date is extended

Prepaid lease payments included in current and long-term prepaid expenses

$389

$306

2,400

1,900

Accounts_Payable_and_Accrued_L2

Accounts Payable and Accrued Liabilities (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Accounts Payable and Accrued Liabilities
Trade payables	$3,164	$6,063
Machinery and equipment payables	2,209	2,270
Accrued expenses	8,342	8,669
Value added tax payable	206	208
Other tax payable	177	576
Withholding tax payable	354	1,511
Bonus and benefit payables	5,626	5,244
Other payables	3,159	3,496
Total	$23,237	$28,037

Income_Taxes_Details

Income Taxes (Details)	12 Months Ended												12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
	USD ($)	USD ($)	USD ($)	USD ($)				Minimum	Maximum	Sinovac Beijing	PRC subsidiaries	PRC subsidiaries	PRC	PRC	PRC	PRC	PRC	PRC	PRC
								USD ($)	USD ($)	USD ($)	USD ($)	CNY		Minimum	Maximum	Sinovac Beijing	Sinovac Beijing	Sinovac Beijing	PRC subsidiaries
																	Future Tax Rate	Future Tax Rate
Income Taxes
Statutory income tax rate (as a percent)	25.00%	25.00%	25.00%	25.00%	25.00%	25.00%	25.00%												25.00%
Preferential income tax rate (as a percent)																15.00%	15.00%	15.00%
Period after which preferential income tax rates need to be reviewed																3 years
Withholding income tax
Withholding tax rate, lower end (as a percent)													5.00%
Withholding tax rate, higher end (as a percent)													10.00%
Income (loss) before income tax
Non - PRC	($1,336)	($65)	($527)
PRC	2,458	8,210	-19,106
Total	1,122	8,145	-19,633
Income taxes attributed to the operations in China
Current	-1,620		867
Deferred	162	2,225	17
Total income tax benefit (expense)	-1,458	2,225	884
Reconciliation of income taxes
Income (loss) before income taxes and non-controlling interests	1,122	8,145	-19,633
Income tax (expense) benefit at the PRC statutory rate	-281	-2,036	4,909
International tax rate differential	-334	-16	-40
Change in unrecognized tax benefitsChange in unrecognized tax benefits	-282	-25	147
Other adjustments	-79	228	59
Permanent differences	362	412	904
Effect of preferential tax treatment	901	1,573	-648
Change in valuation allowance	-1,639	2,089	-5,314
Effect of PRC withholding tax	-106		867
Total income tax benefit (expense)	-1,458	2,225	884
Tax effects of temporary differences giving rise to deferred tax assets
Accrued expenses	2,413	1,982
Inventories	388	729
Prepaid expenses and deposits	-6
Deferred government grants	12
Tax losses carried forward		485
Less: valuation allowance	-541	-594
Deferred tax assets, current portion	2,266	2,602
Fixed assets	1,493	576
Deferred government grants	428
Tax losses carried forward	10,805	10,060
Less: valuation allowance	-12,211	-10,519
Deferred tax assets, non-current portion	515	117
Valuation allowance	12,752	11,113
Carry forward of tax losses
Tax losses carried forward											43,221	262,000
Amount of undistributed earnings										5,420
Amount of unrecognized deferred tax liabilities								271	542
Term of statute of limitation														3 years	10 years
Unrecognized tax benefit
Balance at the beginning of the period	370	345	198
Additions for tax positions of the current year	168	25	147
Lapse of statute of limitations	-56
Balance at the end of the period	482	370	345	198
Interest and penalties recorded		0	0
Potential tax exposures		208	153
Reasonable possible change on the Company's unrecognized tax benefits, low bound	0
Reasonable possible change on the Company's unrecognized tax benefits, upper bound	$361

Deferred_Revenue_Details

Deferred Revenue (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Deferred Revenue
Amount received, included in current deferred revenue	$4,996	$875
Amount received, included in long-term deferred revenue	7,191	11,005
Chinese government stockpiling purchases of H5N1 vaccines
Deferred Revenue
Amount received, included in current deferred revenue	3,546	102
Amount received, included in long-term deferred revenue	7,191	11,005
Advances from customers
Deferred Revenue
Amount received, included in current deferred revenue	$1,450	$773

Deferred_Government_Grants_Det

Deferred Government Grants (Details)

12 Months Ended

In Thousands, unless otherwise specified

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2007

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2009

Dec. 31, 2014

Dec. 31, 2013

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

Beijing Zhongguancun Development Group

Grants for pandemic influenza vaccine

Grants received in 2009 for H1N1

Grants received in 2013 for H5N1

Grants for EV 71 vaccine research and development

Grants received for research and and development, as well as purchasing equipment for EV71 vaccine production

Other research projects

Term Loan For Funding Vaccine Research Project

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

project

Deferred Government Grants

Government grants received

$3,520

21,700

$842

5,200

$936

5,900

20,000

$999

6,200

$3,223

20,000

Deferred government grants

376

383

1,466

1,800

9,100

10,900

630

3,900

500

723

4,500

Current portion of government grants

530

458

290

1,800

143

900

100

500

Non-current portion of government grants

7,494

4,746

1,176

7,300

487

3,000

400

1,525

9,500

642

4,000

578

3,600

Portion of grant recorded as a reduction to depreciation expense

290

237

285

143

119

Number of projects

Number of projects, noncurrent

Loan received

$1,934

12,000

Interest rate (as a percent)

0.36%

Effective interest rate used to calculate fair value differential (as a percent)

6.90%

Commitments_and_Contingencies_1

Commitments and Contingencies (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Operating Lease Commitments
Rental expense	$869	$847	$823
Minimum future rental payments under operating leases
2015	869
2016	869
2017	869
2018	869
2019	869
Thereafter	9,679
Total minimum future payments	14,024
R&D expenditures
Commitments
Other commitments	960
Capital expenditures
Commitments
Other commitments	$5,528

Common_Stock_Details

Common Stock (Details) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
	Vote	Dec. 31, 2013	Dec. 31, 2012
Common Stock
Number of votes on each share of common stock	1
Common stock outstanding (in shares)	55,809,661	55,570,361
Preferred stock issued (in shares)	0	0
Preferred stock outstanding (in shares)	0	0
Common stock issued on exercise of stock options (in shares)			317,600
Exercise price of options exercised (in dollars per share)			$1.60
Proceeds from common stock issued on exercise of stock options	$512	$848	$508
Cash proceeds received on exercise of stock options for which shares were not issued till date	51	18	8
$1.60
Common Stock
Common stock issued on exercise of stock options (in shares)	48,000	360,600
Exercise price of options exercised (in dollars per share)	$1.60	$1.60
$2.37
Common Stock
Common stock issued on exercise of stock options (in shares)	191,300	118,200
Exercise price of options exercised (in dollars per share)	$2.37	$2.37
Employee stock options
Common Stock
Cash proceeds received on exercise of stock options for which shares were not issued till date	$51	$18	$8

Stock_Options_Details

Stock Options (Details) (USD $)	12 Months Ended			0 Months Ended	1 Months Ended	0 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	1-May-12	Dec. 31, 2011	Aug. 22, 2012
Stock Options
Proceeds from Stock Options Exercised	$512	$848	$508
Stock options
Valuation assumptions for stock options
Expected volatility (as a percent)			82.89%
Risk-free interest rate (as a percent)			0.39%
Expected life			2 years 11 months 12 days
Dividend yield (as a percent)			0.00%
Estimated forfeiture rate (as a percent)			10.00%
Additional information related to stock option
Weighted average fair value of options granted (in dollars per share)	$0	$0	$1.08
Stock options \| 2003 Plan
Stock Options
Common stock available under the options plan (in shares)	42,800
Number of shares available for purchase to each holder of stock option	1
Granted (in shares)				50,000	767,000
Vesting percentage for every three months	10.00%
Period for each 10% vesting	3 months
Exercise price for options granted (in dollars per share)				$2.05	$2.37
Percentage of award that vests on the Initial Vesting Date				10.00%
Percentage of award that vests quarterly over a 27 months period after the initial vesting date				10.00%
Period from the Initial Vesting Date for vesting of remaining options excluding options vesting on Initial Vesting Date				27 months
Stock options \| 2012 Plan
Stock Options
Number of shares available for purchase to each holder of stock option	1
Granted (in shares)	0
Number of shares authorized for issuance						4,000,000
Stock options \| Maximum \| 2003 Plan
Stock Options
Percentage of outstanding common stocks reserved for issuance	10.00%
Term of options granted	10 years
Stock options \| Maximum \| 2012 Plan
Stock Options
Term of options granted						10 years

Stock_Options_Details_2

Stock Options (Details 2) (USD $)	12 Months Ended	0 Months Ended	1 Months Ended	12 Months Ended
Stock Options (Details 2) (USD $)	Dec. 31, 2012	1-May-12	Dec. 31, 2011	Dec. 31, 2014
Stock options activity
Exercised (in shares)	-317,600
Weighted Average Exercise Price
Exercised (in dollars per share)	$1.60
Stock options \| 2003 Plan
Stock options activity
Outstanding at the beginning of the period (in shares)				904,400
Granted (in shares)		50,000	767,000
Exercised (in shares)				-239,300
Forfeited (in shares)				-27,900
Outstanding at the end of the period (in shares)				637,200
Vested and expected to vest at the end of the period (in shares)				596,240
Exercisable at the end of the period (in shares)				560,550
Weighted Average Exercise Price
Outstanding at the beginning of the period (in dollars per share)				$2.14
Exercised (in dollars per share)				$2.22
Forfeited (in dollars per share)				$2.37
Outstanding at the end of the period (in dollars per share)				$2.09
Vested and expected to vest at the end of the period (in dollars per share)				$2.08
Exercisable at the end of the period (in dollars per share)				$2.06
Aggregate Intrinsic Value
Outstanding at the beginning of the period				$3,603,712
Vested and expected to vest at the end of the period (in dollars)				1,880,498
Exercisable at the end of the period				1,778,282
Outstanding at the end of the period				$1,997,644

Stock_Options_Details_3

Stock Options (Details 3) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Stock options by range of exercise prices
Options Outstanding - Number of Options Outstanding (in shares)	637,200
Options Outstanding - Weighted Average Remaining Contractual Life	1 year 11 months 9 days
Options Exercisable - Number of Options Exercisable (in shares)	560,500
Options Exercisable - Weighted Average Remaining Contractual Life	1 year 9 months 18 days
Options Exercisable - Weighted Average Exercise Price (in dollars per share)	$2.06
Information pertaining to stock options
Stock-based compensation expense included in selling, general and administrative expenses	$287	$281	$347
Stock options
Stock options by range of exercise prices
Estimated fair value of stock options vested	414	420	631
Stock options \| 2003 Plan
Stock options by range of exercise prices
Unrecognized compensation cost related to non-vested stock options granted	175
Period of recognition of unrecognized compensation expense	3 months
Aggregate intrinsic value of stock options exercised under the Plan	$840	$1,344	$127
$1.60
Stock options by range of exercise prices
Options Outstanding - Number of Options Outstanding (in shares)	227,600
Options Outstanding - Weighted Average Remaining Contractual Life	18 days
Options Outstanding - Weighted Average Exercise Price (in dollars per share)	$1.60
Options Exercisable - Number of Options Exercisable (in shares)	227,600
Options Exercisable - Weighted Average Remaining Contractual Life	18 days
Options Exercisable - Weighted Average Exercise Price (in dollars per share)	$1.60
$2.37
Stock options by range of exercise prices
Options Outstanding - Number of Options Outstanding (in shares)	409,600
Options Outstanding - Weighted Average Remaining Contractual Life	2 years 11 months 27 days
Options Outstanding - Weighted Average Exercise Price (in dollars per share)	$2.37
Options Exercisable - Number of Options Exercisable (in shares)	332,900
Options Exercisable - Weighted Average Remaining Contractual Life	2 years 11 months 27 days
Options Exercisable - Weighted Average Exercise Price (in dollars per share)	$2.37

Statutory_surplus_reserves_Det

Statutory surplus reserves (Details)	12 Months Ended				12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2012	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2014
	USD ($)	CNY	USD ($)	CNY	Sinovac Beijing	Sinovac Beijing	Sinovac Beijing	Sinovac Beijing	Sinovac Beijing	Tangshan Yian	Sinovac R&D	Sinovac Dalian
					USD ($)	CNY	USD ($)	USD ($)	CNY	USD ($)	USD ($)	USD ($)
Distribution of Profit
Minimum percentage appropriation to statutory surplus reserve fund required	10.00%	10.00%
Reserve level threshold for mandatory transfer requirement (as a percent)	50.00%	50.00%
Statutory surplus reserves	$12,627		$11,808
Percentage of after-tax profits appropriated to statutory surplus reserves					10.00%	10.00%	0.00%	0.00%	0.00%
Appropriation of after-tax profits to statutory surplus reserves					819	5,000	0	0
Appropriation of net income after taxes to staff welfare and bonus fund					0		0	0		0	0	0
Appropriation to statutory surplus reserve fund										0	0	0
Dividend declared to non-controlling shareholder					0		0	802	5,000
Dividend payable	0		0
Amount of paid-in-capital and statutory surplus reserves that are restricted from transfer or dividend distribution	80,091	497,000	81,249	492,000
Amount of net assets that are restricted from transferring in the form of loans, advances or cash dividends	$61,345		$34,860

Noncontrolling_Interests_Detai

Non-controlling Interests (Details)	0 Months Ended				0 Months Ended
In Thousands, unless otherwise specified	Oct. 01, 2011	Oct. 01, 2011	Oct. 01, 2011	Sep. 30, 2011	Apr. 08, 2013	Dec. 31, 2014	Dec. 31, 2013
	Sinovac Beijing	Sinovac Beijing	Sinovac Beijing	Sinovac Beijing	Sinovac Beijing	Sinovac Dalian	Sinovac Dalian
	USD ($)	CNY			Sino Bioway
Non-controlling Interests
Increase in ownership (as a percent)	1.53%	1.53%
Increase in ownership by the entity in a subsidiary through contributing dividends declared to another subsidiary, but unpaid	$2,998	18,600
Adjustment charged to additional paid-in capital, resulted from the difference between adjusted carrying amount of non-controlling interest and consideration	$258	1,600
Non-controlling ownership interest (as a percent)			26.91%	28.44%		45.00%	45.00%
Transfer of noncontrolling equity interest to Xiamen Bioway Biotech Co., Ltd. (as a percent)					26.91%

Earnings_loss_per_Share_Detail

Earnings (loss) per Share (Details) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Earnings (loss) per Share
- Net income (loss) attributable to shareholders of Sinovac	($851)	$7,442	($14,853)
Basic weighted average number of common shares outstanding	55,681,076	55,301,276	54,926,440
Effect of dilutive securities:
Stock options (in shares)		501,062
Diluted weighted average number of common shares outstanding	55,681,076	55,802,338	54,926,440
Basic earnings (loss) per share (in dollars per share)	($0.02)	$0.13	($0.27)
Diluted earnings (loss) per share (in dollars per share)	($0.02)	$0.13	($0.27)

Segmented_Information_Details

Segmented Information (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
	item	Dec. 31, 2013	Dec. 31, 2012
Segmented Information
Number of operating segment	1
Segmented information
Assets	$238,530	$240,693
Revenues	63,101	72,524	49,216
Inactivated hepatitis A
Segmented information
Revenues	48,450	47,202	39,951
Seasonal influenza vaccine
Segmented information
Revenues	12,131	12,156	9,191
H5N1
Segmented information
Revenues	201	10,736
Mumps
Segmented information
Revenues	2,150	1,680	24
Rabend
Segmented information
Revenues	169	750	50
PRC
Segmented information
Total long-lived assets	79,174	79,683
Assets	207,645	199,703
Revenues	62,124	71,397	48,199
Hong Kong
Segmented information
Assets	30,885	40,990
Foreign countries
Segmented information
Revenues	$977	$1,127	$1,017

Collaboration_Agreements_Detai

Collaboration Agreements (Details)

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

In Thousands, unless otherwise specified

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Mar. 31, 2015

Dec. 14, 2011

Mar. 12, 2009

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Mar. 12, 2009

Aug. 18, 2009

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Aug. 18, 2009

Aug. 15, 2012

31-May-14

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2014

Apr. 03, 2014

Dec. 31, 2014

USD ($)

Technology Transfer Agreement

Tianjing CanSino Biotechnology Inc.

National Institutes of Health

Medimmune

The Institute for Translational Vaccinology

USD ($)

Technology Transfer Agreement

Patent License Agreement

Licenses

USD ($)

EUR (€)

sIPV

USD ($)

Minimum

Maximum

USD ($)

Minimum

Maximum

H5N1 licenses

USD ($)

EUR (€)

item

USD ($)

item

USD ($)

Maximum

item

USD ($)

Collaboration Agreements

Collaborative agreement, term

8 years

50 years

Milestone payments

$3,000

$9,900

Amount of payment for transfer of an additional serotypes and related technology

300

Number of additional serotypes transferred as per amended agreement

Research and development expenses

11,034

8,384

17,044

200

Royalties included in the account payable and accrued liabilities

1,036

Milestone payments incurred

300

1,200

Milestone payments incurred under the March 12, 2009 agreement

1,000

Milestone payments incurred under the December 14, 2011 agreement

200

License issue royalty

Licenses fees and royalties paid

3,400

Non-refundable annual royalty

Royalty payments on net sales (as a percent)

6.00%

10.00%

1.50%

4.00%

Royalty payments upon achieving each benchmark

330

License issue royalty recorded in research and development expenses

Number of sublicense agreements with termination date revised

Doses of vaccines obtained from the Chinese government

3,000,000

Entrance fees and Milestone payments

2,406

1,500

Entrance fee recorded as research and development expense

665

500

Payment made recorded in research and development expense

$125

€ 94

Subsequent_Events_Details

Subsequent Events (Details)

12 Months Ended

1 Months Ended

In Thousands, unless otherwise specified

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Feb. 28, 2015

Mar. 31, 2015

USD ($)

China Construction Bank

China Merchants Bank

Subsequent events

Line of Credit

China Construction Bank Loan for Changping facility

Bank Term Loan Drawn In March 2014

China Construction Bank

China Merchants Bank

Subsequent events

Sinovac Beijing

China Construction Bank Loan for Changping facility

Bank Term Loan Drawn In March 2014

Bank Of China

USD ($)

CNY

USD ($)

CNY

Sinovac Beijing

Sinovac Dalian

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

Subsequent Events

Repayments of loans

$15,962

$4,089

$4,755

$322

2,000

$322,000

2,000

$13,861

86,000

$4,835

30,000

$806

5,000

Term of debt instrument

1 year

Condensed_Financial_Informatio2

Condensed Financial Information of the Parent Company (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Current assets
Cash and cash equivalents	$91,518	$107,242	$91,241	$104,287
Prepaid expenses and other receivables	1,430	1,150
Total current assets	154,803	157,250
Total assets	238,530	240,693
Current liabilities
Accrued expenses and other payables	8,342	8,669
Total current liabilities	79,834	49,157
Total liabilities	96,804	97,054
EQUITY
Preferred stock Authorized 50,000,000 shares at par value of $0.001 each Issued and outstanding: nil
Preferred stock, Authorized shares	50,000,000	50,000,000
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, Issued shares	0	0
Preferred stock, outstanding shares	0	0
Common stock (note 16) Authorized: 100,000,000 shares at par value of $0.001 each Issued and outstanding: 55,809,661 (2013-55,570,361)	56	56
Common stock, Authorized shares	100,000,000	100,000,000
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, Issued shares	55,809,661	55,570,361
Common stock, outstanding shares	55,809,661	55,570,361
Additional paid-in capital	108,243	107,393
Accumulated other comprehensive income	12,022	14,141
Total shareholders' equity	126,564	128,684
Total liabilities and equity	238,530	240,693
Parent Company
Current assets
Cash and cash equivalents	997	1,400	2,289	3,692
Prepaid expenses and other receivables	9	123
Amount due from subsidiaries	69,824	68,520
Dividend receivables	21,280	21,280
Total current assets	92,110	91,323
Investment in subsidiaries	38,616	40,044
Total assets	130,726	131,367
Current liabilities
Accrued expenses and other payables	584	920
Amount due to subsidiaries	3,578	1,763
Total current liabilities	4,162	2,683
Total liabilities	4,162	2,683
EQUITY
Preferred stock Authorized 50,000,000 shares at par value of $0.001 each Issued and outstanding: nil
Preferred stock, Authorized shares	50,000,000	50,000,000
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, Issued shares	0	0
Preferred stock, outstanding shares	0	0
Common stock (note 16) Authorized: 100,000,000 shares at par value of $0.001 each Issued and outstanding: 55,809,661 (2013-55,570,361)	56	56
Common stock, Authorized shares	100,000,000	100,000,000
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, Issued shares	55,809,661	55,570,361
Common stock, outstanding shares	55,809,661	55,570,361
Additional paid-in capital	108,243	107,393
Accumulated other comprehensive income	12,022	14,141
Accumulated deficit	6,243	7,094
Total shareholders' equity	126,564	128,684
Total liabilities and equity	$130,726	$131,367

Condensed_Financial_Informatio3

Condensed Financial Information of the Parent Company (Details 2) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Operating expenses
General and administrative expenses	$34,787	$34,538	$33,280
Total operating expenses	46,120	42,506	51,267
Loss from operations	488	8,745	-21,151
Interest income	2,685	2,168	2,370
Other comprehensive income(loss), net of tax of nil
Foreign currency translation adjustments	-2,427	2,686	2,024
Comprehensive income (loss) attributable to shareholders of Sinovac	-2,970	9,812	-13,060
Parent Company
Operating expenses
General and administrative expenses	2,466	2,710	3,170
Total operating expenses	2,466	2,710	3,170
Loss from operations	-2,466	-2,710	-3,170
Interest income	759	755	879
Equity income (losses) of subsidiaries, net of tax	856	9,397	-12,562
Net income (loss)	-851	7,442	-14,853
Other comprehensive income(loss), net of tax of nil
Foreign currency translation adjustments	-2,119	2,370	1,793
Comprehensive income (loss) attributable to shareholders of Sinovac	($2,970)	$9,812	($13,060)

Condensed_Financial_Informatio4

Condensed Financial Information of the Parent Company (Details 3) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
- Stock-based compensation	$287,000	$281,000	$347,000
Changes in:
- Prepaid expenses and other receivables	-496,000	242,000	913,000
Accrued expenses and other payables	-4,167,000	4,552,000	-967,000
Net cash provided by (used in) operating activities	-8,647,000	5,576,000	-16,254,000
Cash flows provided by financing activities
- Proceeds from issuance of common stock, net of share issuance costs	512,000	848,000	508,000
- Proceeds from shares subscribed	51,000	18,000	8,000
Net cash provided by financing activities	5,309,000	14,419,000	17,330,000
Cash flows provided by (used in) investing activities
Net cash used in investing activities	-11,003,000	-5,176,000	-16,151,000
Decrease in cash and cash equivalents	-15,724,000	16,001,000	-13,046,000
Cash and cash equivalents, beginning of year	107,242,000	91,241,000	104,287,000
Cash and cash equivalents, end of year	91,518,000	107,242,000	91,241,000
Parent Company
Cash flows provided by (used in) operating activities
Net income (loss)	-851,000	7,442,000	-14,853,000
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
- Stock-based compensation	287,000	281,000	347,000
- Equity in earnings (loss) of subsidiaries	-856,000	-9,397,000	12,562,000
Changes in:
- Amount due from subsidiaries	-1,304,000	2,505,000	-1,283,000
- Prepaid expenses and other receivables	114,000	59,000	25,000
- Dividend receivables		1,043,000	-13,782,000
- Amount due to subsidiaries	1,815,000	1,130,000	-1,792,000
Accrued expenses and other payables	-336,000	-776,000	269,000
Net cash provided by (used in) operating activities	-1,131,000	2,287,000	-18,507,000
Cash flows provided by financing activities
- Proceeds from issuance of common stock, net of share issuance costs	512,000	848,000	508,000
- Proceeds from shares subscribed	51,000	18,000	8,000
Net cash provided by financing activities	563,000	866,000	516,000
Cash flows provided by (used in) investing activities
- Investment in subsidiaries	165,000	-4,042,000	16,588,000
Net cash used in investing activities	165,000	-4,042,000	16,588,000
Decrease in cash and cash equivalents	-403,000	-889,000	-1,403,000
Cash and cash equivalents, beginning of year	1,400,000	2,289,000	3,692,000
Cash and cash equivalents, end of year	$997,000	$1,400,000	$2,289,000